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ABSTRACT 
 
 
Healthy, reproducing cells create and destroy proteins in an ordered manner.  
Both the concentration and localization of protein pools is important to regulate the many 
cellular processes necessary for the life of the cell.   In order to produce new proteins, 
cells degrade existing materials such as proteins and organelles that are dispensable or 
troublesome in order to recycle their raw components.  Degradation is accomplished 
largely through two major pathways:  in bulk through processes such as autophagy and 
phagocytosis, or in a targeted manner through the ubiquitin-proteasome pathway.  
Autophagy utilizes an encompassing body to encapsulate targets and surrounding 
materials for decomposition in a regulated but relatively non-specific manner.  The 
ubiquitin-proteasome pathway, however, is an exquisitely precise method of degradation 
capable of targeting specific pools of protein substrates.  So-called ubiquitination 
generates a signal for degradation by the 26S proteasome machinery.  In order to 
establish the degradation signal, the cell utilizes a cascade of 3 enzymes working in 
concert to organize substrates and ubiquitin.  By using enzymes capable of substrate 
specificity, the cell can regulate large pools of proteins in a specific spatio-temporal 
manner.    
 
 In the present study, we employ biochemical and structure-based techniques to 
study proteins involved in an essential ubiquitination pathway involved in maintenance of 
the cell cycle.  A mitotic regulator called the Anaphase Promoting Complex, also called 
Cyclosome (APC/C), modifies myriad substrates that control cell cycle activities.   The 
APC/C is a ubiquitin ligase complex; it is the final enzyme in a tri-enzyme cascade and 
catalyzes the final step of Ub transfer from an E2 enzyme directly to substrates.  A 
protein called Emi1 is responsible for directly binding and inhibiting the APC/C 
throughout interphase, when APC/C substrates are stabilized.  We set out to study 
domains of Emi1 responsible for binding and inhibiting the APC/C and its association 
with E2 enzymes or substrates, with the aim of characterizing both the mechanism of the 
inhibitor and the essential functional requirements of the APC/C, which are not well 
understood.  We aim to visualize the APC/C in complex with Emi1 through electron 
microscopy and to accurately interpret the location and orientation of Emi1 within this 
density. 
 
 The APC/C is a large, ~1,200 kDa multi-protein complex, and Emi1 is a single 
protein of only 50 kDa.  Despite its small size, even a small subdomain of Emi1 potently 
inhibits the APC/C through a combination of not well-characterized mechanisms.  Emi1 
has an APC/C recognition motif called a D-box that is typically found within APC/C 
substrates.  Emi1’s D-box is recruited to the substrate-binding sites of APC/C and serves 
as a pseudo-substrate inhibitor.  Emi1 also inhibits through distinct mechanisms both of 
the E2 enzymes that coordinate with APC/C function.  An essential, folded Zinc-binding 
Region (ZBR) and a helical “Linker” sequence cooperate to bind and block APC/C from 
recruiting one of two APC-specific E2 enzymes, Ubch10.  Emi1 also has a conserved C-
terminal motif, with charge and sequence similar to the other APC/C- specific E2 
enzyme, Ube2s.  Emi1 competes directly with Ube2s for APC/C recruitment, and it is 
 vii 
through the combination of these three mechanisms that are afforded by many motifs 
within Emi1, that makes Emi1 a potent APC/C inhibitor.  When associated with Emi1, 
the APC/C is inefficient at both recruiting substrates and binding E2 enzymes, allowing 
for stabilization of APC/C substrates, which is important for regulation of timing of cell 
cycle processes. 
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CHAPTER 1.    INTRODUCTION 
 
 
Introduction to the Ubiquitination Pathway for Selective Protein Degradation 
 
The attachment of a 8.5 kDa protein called Ubiquitin to target proteins is essential 
to eukaryotic cellular fitness and survival.  This conjugation of Ubiquitin, termed 
Ubiquitination, to innumerable substrates is in some way involved in every process and 
signaling pathway that the cell employs for function.  Ubiquitination, does not occur 
randomly, but through the activities of a selective cascade of enzymes.  This form of 
post-translational modification is similar in scope and importance to phosphorylation.  
Modification of substrates with Ubiquitin (Ub) can alter the function or fate of the target 
by directing the localization, conformation, interactions, or degradation of the target 
protein through targeting to proteasomal machinery for proteolysis and amino acid 
recycling. 
 
 
The Ubiquitin Protein as a Signaling Moiety 
 
The Ubiquitin protein itself is small, only 76 amino acids, with a globular 
structure.  Many important features are contained within this 8.5 kDa protein that make it 
a versatile signaling moiety.  Notably, a C-terminal di-Gly (GG) motif directs thioester 
bond formation with Cysteine residues and isopeptide bond formation with primary 
amines typically found in Lysine side-chains within proteins.  Ubiquitin itself contains 7 
Lysine residues and an intact N-terminal primary amine, so is accordingly also a target 
for modification in 8 ways.  The conserved structural fold of Ubiquitin exposes all 7 of its 
own Lysines (K6, K11, K27, K29, K33, K48, K63) for modification by other Ubiquitin 
molecules. (Figure 1-1)  Multiple modifications of this type, called polyubiquitination, 
generates a variety of morphologically and functionally distinct chains (Varadan, Walker 
et al. 2002, Tenno, Fujiwara et al. 2004).  For instance, chains formed by modification of 
Ubiquitin’s Lys 11, have a different signaling output from chains of Lys 63.  So-called 
K11-linked chains are targeted for proteasomal recognition, while K63 chains direct 
cellular signaling (Dikic, Wakatsuki et al. 2009, Komander and Rape 2012, Berndsen and 
Wolberger 2014). To compound the system’s complexity, target proteins may be 
modified on several different lysines concurrently, with either homotypic or heterotypic 
linkages, or with branched chains consisting of a mixture of Ub-linkages.  The extent and 
topology of substrate-linked ubiquitin chains is thought to directly influence the rates of 
substrate degradation and is an important area of active research (Hershko and Heller 
1985, Ikeda and Dikic 2008, Komander and Rape 2012).  
 
 
Ubiquitin Is Attached to Substrates by an Enzymatic Cascade 
 
 Regulation of such a complex signaling system is achieved by directed attachment 
of Ubiquitin through the concerted action of three classes of enzymes. (Figure 1-2)  
Firstly, a Ubiquitin activating enzyme, also called E1, binds and activates Ubiquitin by  
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Figure 1-1. Ubiquitin as a Signaling Moiety. 
 
Structural Representation of Ubiquitin from the Protein Data Bank (1UBQ.pdb) with 7 
surface-exposed Lysine residues represented as magenta sticks, and the C-terminal Gly-
Gly motif represented as orange sticks.  Heterotypic chains contain multiple different 
Ubiquitin linkages, whereas homotypic chains arise from repeats of a single Ub linkage. 
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Figure 1-2. Enzymatic Cascade for Substrate Ubiquitination. 
 
Ubiquitin, yellow sphere, is conjugated to the E1, shown in pink, in an ATP-dependent 
step.  E1~Ub then transfers to an E2 enzyme, shown in orange, which collaborates with 
E3 enzymes of several types, shown in green.  Cullin-RING and Simple RING E3s 
coordinate E2~Ub and substrates for direct transfer, whereas HECT and RBR E3s 
participate in the reaction. 
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ATP-dependent adenylation of its C-terminal Glycine residue.  Following thioester 
linkage of Ubiquitin to a Cysteine residue within the E1, Ubiquitin’s C-terminus is 
transferred to a Cysteine residue within a conjugating enzyme, also called E2.  This 
E2~Ubiquitin bond is also a labile, thioester bond, and Ubiquitin is easily discharged to 
form an isopeptide bond with substrate Lysines when the E2~Ubiquitin conformation is 
appropriate and substrate is properly positioned as an acceptor (Pickart and Eddins 2004, 
Eletr, Huang et al. 2005, Ye and Rape 2009). In many cases this catalytic architecture is 
achieved through a third, ligating enzyme, also called an E3 enzyme.  Over 600 E3 
ligases are known to catalyze Ubiquitin transfer through a variety of mechanisms 
discussed later in this document.  Generally speaking, E3 ligases recruit both Ubiquitin-
loaded E2s and substrates to both position and mechanistically facilitate Ubiquitin 
transfer.  
 
 
Understanding the Transfer of Ubiquitin from E1 to E2 Enzymes 
 
 Much of what we currently understand about the nature of the E1-E2 Ubiquitin 
transfer reaction comes from early work in our own lab (Huang, Miller et al. 2004, 
Huang, Paydar et al. 2005).  By studying an analogous cascade of Neddylation, wherein a 
Ubiquitin-like protein called Nedd8 is transferred through a similar tri-enzyme cascade, 
the authors showed how a heterodimeric E1, APPBP1-UBA3, recruits the E2, UBC12.  
APPBP1-UBA3 harbors an N-terminal strand from UBC12 for optimal recruitment, and 
simultaneously provides a Ubiquitin-like (UBL) domain which binds the E2 mimicking a 
standard Ubiquitin interaction with a Ubiquitin-binding domain.  Though E1 and E2 
interactions were characterized, what confounded researchers was a large gap between 
where Ubiquitin’s C-terminus was bound to the E1, and where it was going to bind on the 
E2 catalytic cysteine.  The authors suggest that a substantial conformational reorientation 
would be required to place the E1 and E2 catalytic cysteine residues in close proximity.  
This rearrangement was later visualized for Ubiquitin through active-site disulfide 
crosslinking of UBA1-UBC4~Ubiquitin (E1-E2~UB) (Olsen and Lima 2013). These 
observations underscore much of the mechanism of ubiquitination intermediates: proteins 
are first recruited together through a variety of interactions, and subsequent 
conformational changes create a chemical environment suitable for faithful transfer of 
Ubiquitin through the enzymatic cascade or to the substrate. 
 
 
E2 Enzymes Coordinate with Functionally Distinct Families of E3 Ligases to 
Transfer Ubiquitin to Substrates 
 
 E3 enzymes have been categorized into functional classes including HECT-type, 
RING-IBR-RING, simple RING, and Cullin-RING.  HECT and RING-IBR-RING 
ligases not only bring Ub~E2 in proximity to substrate, but also receive Ubiquitin to 
participate in the reaction.  Cullin-RING proteins, on the other hand, utilize substrate-
binding modules called substrate adaptors to provide multifunctionality to a small group 
of nine Cullin proteins (Figure 1-2).  By recognizing first a wide variety of adaptors that 
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can each recognize a variety of substrates, cells can achieve both regulation and substrate 
specificity across the many thousand targets of Cullin-RING ubiquitination. 
 
Cullin-RING ligases (CRLs) are the largest family of E3 ligase complexes.  
Within this family, architecture nucleated by a Cullin protein precisely positions the Ub-
thioester-E2 adjacent to the substrate (Willems, Schwab et al. 2004, Sarikas, Hartmann et 
al. 2011).  This example of structural scaffolding underscores one important feature of E3 
ligase activity: E3s utilize several accessory proteins to recruit and organize a variety of 
substrates with specific Ub-loaded E2s to mediate catalysis.  Serving as an assembly 
platform for the E2 and substrate is not the only role for E3 enzymes, though.  E3s also 
activate E2 enzymes for transfer of otherwise stable E2~Ub conjugates. (Wu, Hanlon et 
al. 2003, Summers, Pan et al. 2008).  
 
 
Cullin-RING E3s Utilize a Cullin Protein to Scaffold E2 and Substrate Interactions 
with a Flexibly Tethered RING Domain 
 
 Though only nine Cullin proteins have been discovered so far, their utilization of 
a variety of types of substrate adaptor complexes gives them an impressive family size of 
over 600 genes, more than are involved in the well-studied process of protein 
phosphorylation (Deshaies and Joazeiro 2009).  Included in these genes are those that 
encode proteins containing a RING domain (Really Interesting New Gene)(Freemont, 
Hanson et al. 1991, Deshaies and Joazeiro 2009), collectively called RING proteins.  
Cullin and RING proteins coordinate with substrate adaptors and E2 enzymes, and are 
commonly referred to as the CRL pathway of protein ubiquitination, for Cullin-RING 
ligase.  Essential to the catalytic function of CRLs, RING proteins are responsible for 
binding and activating E2 enzymes for Ubiquitin release.  RING domains, which are 
flexibly tethered to Cullins by association into an intermolecular Beta sheet, are capable 
of loose rotation relative to Cullin.  Through this motion, RINGs bind a loaded E2 on a 
conserved face of the RING’s surface, and bind the substrate proximal to the acceptor 
lysine (Dou, Buetow et al. 2012, Plechanovova, Jaffray et al. 2012, Pruneda, Littlefield et 
al. 2012, Scott, Sviderskiy et al. 2014). 
 
 
Introduction to the Cell Cycle 
 
 Cellular reproduction occurs first by duplication of all cellular components and 
then separation to equal halves of the cell before splitting into two daughter cells.  
Faithful duplication and separation of genomic DNA is essential to proper cell division 
and cellular fitness, so the events surrounding these processes have been divided into four 
functional phases of a highly regulated cell cycle.  Catastrophic failure of either genome 
duplication or DNA distribution leads to cell cycle arrest and eventual cell death.  Failure 
to arrest can lead to aneuploidy, developmental defects such as trisomy, and cancer 
(Penas, Ramachandran et al. 2011, Bochis, Fetica et al. 2015).  Though the relative 
fraction of the four phases of the cell cycle is variable with cell type, a considerably large 
fraction of eukaryotic cell life is spent in Gap-phases where the cells recover from 
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stresses and prepare for growth and development with time-consuming processes such as 
protein expression and organelle growth (Figure 1-3).  
 
 
The Cell Cycle Consists of Four Distinct Phases 
 
Following a Gap-phase called G1, cells enter the synthesis phase (S-phase) 
wherein the entire genome is faithfully replicated to produce an identical set of twin 
chromatids, called sister chromatids.  These sister chromatids are held together by several 
protein complexes throughout the next Gap-phase, G2, until entering the division phase, 
called M-phase (Mitotic phase).  During mitosis, cells progress through a number of 
checkpoint stages characterized by molecular functions occurring within the cell.  A 
crucial checkpoint in mitosis occurs between metaphase and anaphase, where the cell 
must decide whether DNA can be properly segregated into 2 identical halves and can 
therefore proceed through cytokinesis, or division of the cell body to two daughter cells.  
Without completion of this Spindle Assembly Checkpoint, for instance, cells will arrest 
in late metaphase and wait for molecular signals suggesting they are ready to progress.  
Completion of the Spindle Assembly Checkpoint releases the aptly named Anaphase 
Promoting Complex, which ubiquitinates and destroys many essential cell-cycle 
regulatory proteins.  Degradation of these proteins drives the cell cycle thorough 
metaphase to Anaphase, allowing for eventual cell division.  These duplicated cells then 
enter G1 phase again, growing and preparing to repeat the process again.  
 
 
Cells Polarize Their Genetic Information and Organize Division in the Mitotic 
Phase 
 
 During mitosis, two sister chromatids of identical genetic information are 
organized along a central axis and divided to opposite poles through the action of a large 
number of protein activities.  To do this consistently in a regulated and concerted way, 
the intracellular space undergoes severe morphological changes that can be classified to a 
number of distinct mitotic phases named Prophase, Pro-metaphase, Metaphase, 
Anaphase, and Telophase.  In Prophase and Pro-metaphase, following nuclear envelope 
breakdown (NEBD), the DNA is compacted and folded into chromatids held together by 
kinetochores to make mitotic chromosomes.  These chromatids are aligned to a central 
axis by spindle fibers in Metaphase.  Following proper bi-orientation, where each sister 
chromatid of each chromosome is tethered to opposite spindle poles, the APC/C is 
released from the Spindle Assembly Checkpoint and becomes active.  Immediately prior 
to Anaphase, APC/C-mediated degradation of a substrate called Securin allows an 
enzyme called Separase to cleave Cohesin.  Cohesin cleavage disassembles the 
kinetochore and allows for each chromatid to be separated by microtubule motor proteins 
to opposite spindle poles within the cell.  During Telophase, two nuclear membranes 
reform around the chromosomes, which unwind into chromatin.  At the end of Telophase, 
the cell body is split in a process called cytokinesis and two identical cells enter G1 phase 
to complete and restart the cycle.  
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Figure 1-3. Schematic Diagram of the Cell Cycle. 
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The Anaphase Promoting Complex/Cyclosome 
 
 The Anaphase Promoting Complex, simultaneously discovered and named the 
Cyclosome, is a large assembly of at least 18 proteins expressed from 14 genes.  It was 
discovered as an E3 Ubiquitin ligase for its role in Cyclin degradation at the end of 
mitosis in collaboration with an E2 enzyme called Ubch10 (King, Peters et al. 1995, 
Sudakin, Ganoth et al. 1995).  
 
The APC/C remains assembled throughout the life of the cell but exists in an 
inhibited state following mitosis and completely through interphase.  This allows for 
accumulation of APC/C substrates that are essential for chromosomal duplication and cell 
maintenance.  Only when released from two major inhibitors, Emi1 and MCC, and by 
association with accessory coactivator proteins, Cdc20 or Cdh1, does the APC/C become 
active for ubiquitination of target substrates.  Substrates of the APC/C include a variety 
of cell-cycle regulatory proteins, notably mitotic Cyclins and a number of kinases.  It has 
been suggested that the final stages of mitotis are governed exclusively by 
dephosphorylation of Cdk substrates and by the APC/C-mediated degradation (Morgan 
2007). 
 
 
The APC/C Is Comprised of Many Subunits 
 
 The APC/C is a large complex of structurally diverse proteins (Peters 2006).  The 
complex has been divided into rough halves, where an arc-lamp provides structural 
scaffolding through a number of semi-repetitive TPR-repeat containing proteins as well 
as substrate recruitment, and a platform provides the basis for catalysis (Figure 1-4).  
Structural conservation among the TPR repeat proteins APC7, APC8, APC3, and APC6, 
present as homodimers and held together by Cdc26 and APC16, provide a wall of helices 
surrounding an inner core (Zhang, Chang et al. 2013).  These arc-lamp proteins also 
provide multiple docking points for the coactivators Cdh1 and Cdc20; two proteins 
responsible for recruitment of substrates to the complex, discussed later in this document.  
The structural diversity of the platform provides several mobile points of contact for 
catalytic machinery such as E2 enzymes and substrates.  This gives rise to an overall 
architecture that looks similar to a cupped left hand.  With fingers for the arc-lamp and 
the palm for platform, a central cavity is formed, inside which catalysis is presumed to 
occur.  Importantly, along with APC1, APC4, APC5, APC15, and APC10, the APC/C 
platform contains a cullin and RING module comprised of APC2 and APC11, 
respectively(Schreiber, Stengel et al. 2011).  APC2 primary sequence suggests it contains 
3 cullin-repeats at its N-terminus, a C-terminal four-helix bundle and alpha-beta domain 
and is terminated by a WHB domain, similar to other cullin proteins (Duda, Borg et al. 
2008).  APC11 is a small protein of only 9.8kDa, but it is predicted to be structurally 
homologous to the other small RING proteins Rbx1 and Rbx2 with a number of 
conserved Cysteine residues for coordination of 3 Zinc ions.  Therefore the APC/C is 
speculated to utilize a Cullin-RING type mechanism, as discussed previously. 
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Figure 1-4. Overall Architecture of the APC/C. 
 
Left, Schematic representation of the APC/C with Cdh1 and APC10 poised to corecruit 
substrate D-boxes, and APC11 positioned to perform catalysis.  Right, EMDB-2354 
shows APC/C-Cdh1-Emi1-Skp1 with labels for subunits contributing to density. 
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The APC/C Coordinates with Coactivator Proteins Cdc20 and Cdh1 to Recruit 
Substrates and Activate the Platform for Catalysis 
 
 Cdc20 (Cell Division Cycle 20) and its homolog Cdh1 (for Cdc20 Homolog 1) 
were discovered for their role in maintenance of cell division in Saccharomyces 
cerevisiae (Visintin, Prinz et al. 1997).  Both of these proteins binds to the APC/C at the 
same position, and therefore compete for binding (Nagai and Ushimaru 2014).  Levels of 
Cdc20-bound and Cdh1-bound APC/C are distinct throughout the cell cycle, as pools of 
these proteins are not constant and binding is competitive.  Early in mitosis, Cdh1 levels 
are decreased and APC/C-Cdc20 exists predominantly.  Following the metaphase to 
anaphase transition, Cdc20 becomes a target of APC/C-mediated degradation and 
APC/C-Cdh1 is the dominant complex throughout the rest of the cell cycle (Morgan 
2007).  The APC/C collaborates with Cdc20 and Cdh1 for two primary reasons; substrate 
recruitment and platform activation.  The 7-bladed WD40 B-propeller domain common 
to both Cdc20 and Cdh1 provides a single, well-studied docking surface for recruitment 
of a “degron-motif” common to APC/C substrates, as well as other surfaces that aid in 
recruitment of secondary motifs.  Substrates present an exposed RxxLxxx(x)N motif 
which is recruited by bipartite mechanism to both the coactivator and a nearby subunit 
called APC10 (da Fonseca, Kong et al. 2011).Secondary substrate motifs such as the 
ABBA (first characterized in Cyclin A, Bub3, BubR1, and Acm1) motif and KEN-box 
(Lys-Glu-Asn) are further coordinated by the coactivator (Tian, Li et al. 2012, He, Chao 
et al. 2013).  APC/C recognition of substrates by multiple motifs of varying affinity is 
thought to be a mechanism for coordinating specificity and timing of substrate turnover.  
In more recent studies (Chang, Zhang et al. 2015) it has been shown that an N-terminal 
C-box motif of Cdc20 and Cdh1 enhances coactivator binding and APC/C activation 
independent of substrate recruitment. 
 
 
Many Substrates Are Targeted for Destruction by the APC/C 
 
 The APC/C ubiquitinates a large number of proteins involved in cell cycle 
regulation.  In one example, Cyclins are a group of proteins that were named for the 
cyclic fluctuation of their expression levels throughout the lifetime of S. cerevisiae cells.  
The characterization of these proteins, of which there are several, to be found in repeating 
cycles of high and low concentration was the first evidence for what is known today as 
the cell cycle (Evans, Rosenthal et al. 1983). Cyclins are regulatory proteins for Cyclin-
dependent Kinases (CDKs), a group of kinases with critical functions throughout the cell 
cycle.  Therefore cyclic levels of Cyclin proteins leads to fluctuations in CDK activity, 
and drives the cell cycle forward.  A- and B-type Cyclins are bonafide substrates of the 
APC/C, and this underscores the role of the APC/C in regulating cell-cycle progression.  
The APC/C also targets many other mitotic proteins including Aurora, Polo-like Kinase 1 
(PLK1), Nek2a, Securin, and parts of the APC/C machinery itself including the Cdh1 and 
Ubch10 (Ostapenko, Burton et al. 2012, Lu, Hsiao et al. 2014, Lu, Girard et al. 2015).  
Degradation of this large group of cell-cycle regulatory proteins in an ordered and 
specific way allows the APC/C to orchestrate and direct progression through mitosis and 
then regulate its own activity in trans following completion of anaphase.  Detailed 
 11 
information about substrate selection and temporal regulation of ubiquitination 
surrounding the cell cycle represents an active area of research. 
 
 
Primarily Two E2 Enzymes Work in Conjunction with the APC/C to Deliver 
Ubiquitin  
 
 The APC/C is a Cullin-RING E3 ligase.  As such, it brings together a substrate 
and a Ub-loaded E2 to catalyze direct ubiquitination of the substrate.  The APC/C has 
two dedicated E2 enzymes called Ubch10 (sometimes called Ube2c), and Ube2s.  
Ubch10 utilizes canonical activating residues on the APC11 RING domain, and thus 
participates in a relatively standard Ubiquitination process.  It has been shown that 
Ubch10 prefers to modify lysines on substrates rather than on Ubiquitin itself, and 
therefore builds only very short chains and many single Ubiquitins decorated on the 
substrate surface (Yu, King et al. 1996, Lin, Hwang et al. 2002).  Ube2s, however, is a 
chain-elongation enzyme similar in function to Cdc34 for other CRLs.  Ube2s can only 
attach a Ubiquitin to the Lysine (typically K11) of another Ubiquitin and has essentially 
no capacity to modify APC/C substrate Lysines directly (Garnett, Mansfeld et al. 2009, 
Wu, Merbl et al. 2010).  Though the Ube2s reaction is simplified to a single modification, 
it occurs rapidly and repeatedly, building long K11-linked homotypic chains, which have 
been shown to be essential for mitotic progression (Min, Mevissen et al. 2015).  
Interestingly, mutations of RING residues within APC11 that are deficient for canonical 
E2 enzyme activities have no profound effect on Ube2s activity, suggesting a novel, yet 
undiscovered mechanism of ubiquitination (Brown, Watson et al. 2014). 
 
 
The Mitotic Checkpoint Complex Binds to the Core of APC/C and Inhibits Function 
 
 The APC/C is engaged not only by E2 enzymes, coactivators, and substrates for 
activity, but also by inhibitors such as the Mitotic Checkpoint Complex (MCC) and 
Emi1.  In the early stages of mitosis, an MCC comprised of four proteins (Mad2, Bub3, 
BubR1, Cdc20) binds directly to the APC/C and inactivates destruction of several 
substrates.  Interestingly, certain APC/C substrates like Nek2a and Cyclin A are still 
targeted, presumably by an MCC-bound APC/C through unknown mechanisms.  
Following cell cycle progress cues, the APC/C is released from MCC, and causes 
destruction of its full suite of substrates, including Cyclin B and Securin – factors 
responsible for promotion to Anaphase.  A low-resolution electron microscopy structure 
of an MCC-bound APC/C reveals a probable model for how the MCC blocks APC/C 
activity (Herzog, Primorac et al. 2009, Chao, Kulkarni et al. 2012).  The structural data, 
when analyzed both as Apo-APC/C and MCC-APC/C, shows substantial electron density 
within the central cavity of APC/C only when bound by the large MCC. The MCC likely 
binds to and blocks APC/C catalytic functions as a competitive inhibitor through direct 
binding of the catalytic core of APC/C,. 
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Emi1 Is Responsible for Inhibition of the APC/C Throughout Interphase 
 
 Another protein called Emi1, for Early Mitotic Inhibitor 1, is also thought to 
directly bind and inhibit the APC, albeit through unknown mechanisms.  In stark contrast 
to the multi-protein, ~300 kDa checkpoint complex and the ~1,200 kDa APC/C, Emi1 is 
relatively small at only 50 kDa.  Unlike the MCC, Emi1 has not been structurally 
characterized in complex with the APC/C, and its mechanism is presumed to be unique 
due to the massive difference in size.   
 
 
Emi1 – The Interphase Inhibitor of APC/C Polyubiquitination 
 
Emi1 was first discovered as Rca1 in fruit fly genetic screens in 1997 (Dong, 
Zavitz et al. 1997), and was introduced as Fbxo5 in 1999 from a yeast two-hybrid screen 
for proteins that bind to Skp1, a well-known substrate-adaptor for the Cullin-RING 
family of E3 ligases (Cenciarelli, Chiaur et al. 1999, Latres, Chiaur et al. 1999).  It was 
then rediscovered in Xenopus laevis in 2001 using similar methodology, and 
characterized as an inhibitor of APC/C activity early in mitosis (Reimann, Gardner et al. 
2001).  A closely related homolog, Emi2, shares similar domain architecture with Emi1, 
and plays a similar role in the Xenopus meiotic cycle, so for the sake of simplicity, I will 
highlight only the features of Emi1.  In addition to cycles of expression and assembly of 
the APC/C, Emi1 association and inhibition also occurs cyclically.  Throughout 
interphase the APC/C is found in its inhibited state and only at the onset of mitosis is 
Emi1 removed and degraded, allowing the cell to precisely control both the timing and 
order of substrate degradation, targeted by the APC/C, which is an important prerequisite 
for maintenance of the cell cycle.  
 
 
Multiple Domains of Emi1 Are Suggested to Participate in APC/C Inhibition 
 
 At the onset of our investigation, putative domains of Emi1 had been discovered, 
but had not been thoroughly characterized for APC/C-specific function (Figure 1-5).  
Emi1 residues ~250-300 contain an F-box motif (named for its discovery first in Cyclin 
F) by which Emi1 was discovered.  F-box domains are structural motifs that mediate 
protein-protein interactions, and are usually involved in Cullin-mediated ubiquitination 
pathways.  The F-box fold interacts with other motifs such as the Leucine-Rich Repeat 
(LRR) and WD-40 motifs that are often involved in CRL substrate presentation 
(Cenciarelli, Chiaur et al. 1999).  Residues ~360-420 of Emi1 contain primary sequence 
hallmarks that are conserved in a structural motif called a Zinc-Binding Region (ZBR).  
Zinc ions are coordinated by regularly spaced Cysteine and Histidine residues and are 
necessary for maintaining tertiary structure of this motif.  Indeed, mutation of Cysteine 
residues thought to coordinate Zinc abrogates Emi1 function (Reimann, Freed et al. 2001, 
Tang, Wu et al. 2010).  An extreme C-terminal Arginine-Leucine (RL) motif, called the  
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Figure 1-5. Domain Orientation of Emi1 to Scale. 
 
Emi1 has a large N-terminal domain unimportant for APC/C association, a folded F-box 
domain that associates with Skp1, a small D-box motif, Linker Region, Zinc-Binding-
Region, and C-terminal LRRL tail. 
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RL-tail, has been proposed to aid in recruitment of both Emi1 and Emi2 to APC/C 
through direct binding (Ohe, Kawamura et al. 2010).  Deletion of these residues of Emi2 
ablates binding to endogenous APC/C, as evidenced by an inability to co-IP APC/C from 
Xenopus oocytes.  
 
 
Emi1 Itself Is Regulated by Phosphorylation and Ubiquitination by SCF 
 
 Emi1 itself is a substrate of CRL-mediated ubiqutination and subsequent 
proteasomal degradation.  The N-terminal domain of Emi1 contains a variety of motifs 
which are recognized by both kinases and CRL machinery to provide controlled 
mechanisms of Emi1 destruction.  First, a pair of Serines at residues 145 and 149 within 
Emi1 are phosphorylated by Polo-like Kinase 1 (PLK1) in an Evi5-dependent manner.  
When Evi5 is not associated with Emi1, PLK1-mediated phosphorylation creates a well-
characterized phospho-degron DSGxxS (Residues 144-149) motif for SCF recruitment.  
β-TrCp, an SCF substrate adaptor protein, binds Emi1’s phospho-degron and promotes 
SCF-dependent Emi1 turnover (Margottin-Goguet, Hsu et al. 2003, Hansen, Loktev et al. 
2004).  Despite knowledge of these mechanisms of Emi1 destruction, the context of its 
regulation is not known.  Two possible scenarios could describe the relationship between 
Emi1’s own regulation and its inhibition of APC/C.  In one scenario, Emi1’s N-terminus 
could be protected from recognition by interaction with the APC/C.  Alternatively, Emi1 
N-terminus may be only flexibly tethered to the APC/C through C-terminal contacts, 
allowing constant phosphorylation, ubiquitination, and degradation.  In the second 
scenario, it is also conceivable that phosphorylation or ubiquitination of Emi1 could 
either enhance APC/C binding, or provide a mechanism for liberation of APC/C.  
However, there is no direct evidence for regulation of Emi1 while associated with APC/C 
yet, and the mechanism of dissociation is not well understood.  Emi1 is also regulated at 
the transcriptional level by a transcription factor called E2F.  Its transcription is induced 
at the G1/S-phase transition, enhancing APC/C inhibition and substrate stabilization 
(Hsu, Reimann et al. 2002, Verschuren, Ban et al. 2007). 
 
 
Specific Timing and Localization of APC/C Inhibition Within the Cell Cycle 
 
 Emi1’s inhibition of the APC/C is critical to prevent premature degradation of 
Cyclins and other cell cycle kinases.  Emi1 levels increase following mitosis and APC/C 
remains in an inhibited state throughout interphase.  Even during the early stages of 
mitosis, while Cyclin B activates Cdk1 to drive spindle assembly, APC/C must be 
inhibited.  To inhibit APC/C specifically at the location of spindle assembly, Emi1 is 
recruited through an interaction with a NuMa/Dynein-dynactin complex.  This localizes 
Emi1 to the spindle poles and therefore any APC/C at the poles is efficiently inhibited, 
and Cyclin B is not degraded (Ban, Torres et al. 2007).  Following phosphorylation and 
degradation of Emi1, the APC/C is bound by MCC until completion of the Spindle 
Assembly Checkpoint (SAC).  By unknown mechanisms, MCC disassembles from the 
APC/C, which is finally able to rapidly degrade a number of cell cycle regulatory 
proteins and drives the cell cycle forward.  
 15 
Aims of This Study 
 
 In the present study, I aim to characterize how Emi1, a protein dwarfed in size by 
its target, is capable of reducing the activity of APC/C to negligible levels throughout 
most of the cell cycle; this allows a functional APC/C to be assembled and ready to 
efficiently degrade cell cycle regulatory components only when the cellular environment 
is ready.  Protein-protein interactions often mediate the activity or accessibility of 
enzymes and thus change the outcome.  As mentioned above, the Anaphase Promoting 
Complex utilizes these interactions to attract its substrates and cofactors and catalyze the 
degradation of these substrates.  As a form of regulation, the cell has also developed 
another protein that potently inhibits the APC/C by unknown mechanisms, and it is 
speculated that this inhibition is also mediated through protein-protein interactions..  
 
 To characterize Emi1 function, I will establish protocols for expression and 
purification of many constructs of the Emi1 gene.  With sufficient quantity of pure Emi1 
proteins, and the capacity to make mutations, we can begin to probe the functionality of 
Emi1 in APC/C-dependent ubiquitination assays.  Using established in vitro enzyme 
assays designed to monitor APC/C ubiquitination efficiency, we can saturate with Emi1 
preemptively to counteract the activity of APC/C.  I will utilize this system to establish 
baselines for how effectively mutants of Emi1 inhibit these reactions. 
 
 In parallel, Emi1 will be used both as the subject and critical tool for electron-
microscopy studies with APC/C-Cdh1.  EM density calculations systematically exclude 
mobile elements within protein complexes.  Further micro-fluctuations of the meta-
structure of large complexes limits the resolution obtainable by this method.  Emi1 will 
therefore be used in EM studies not only in attempt to characterize its location and 
function, but also in attempt to stabilize the APC/C and therefore improve the structure 
determination processes.   
 
 Following a comprehensive analysis of Emi1 interactions with APC/C, the 
interaction will be further exploited to develop methods by which other APC/C 
interactions can be studied.  With Emi1 as a positive control for APC/C association, 
protocols will be developed for incorporation of a photoactivatable crosslinking reagent 
designed to inform on site-specific localization of protein-protein interactions.  In brief, 
an unnatural amino acid called p-BPA will be incorporated to a single site within Emi1.  
Following association with APC/C, crosslinking will be activated and information about 
the interaction is revealed.  This technique is both complementary to other biochemical 
and structural studies of Emi1-APC/C, and also provides a framework to study less 
tractable APC/C interacting partners.  For instance, Ube2s interacts with the APC/C only 
transiently, and cannot be visualized through electron microscopy.  Following 
optimization and confirmation of Emi1 crosslinking, analagous experiments can be 
performed with Ube2s to stabilize and characterize otherwise unobservable interactions. 
 
  
 16 
CHAPTER 2.    EXPRESSION AND PURIFICATION OF EMI1 AND UBE2S FOR 
BIOCHEMICAL AND STRUCTURAL STUDIES 
 
 
Emi1 Expression and Purification 
 
Initial characterization of Emi1 includes describing which of the known or yet 
undiscovered motifs are contributing to the functionality of Emi1.  To this end, we 
designed expression constructs systematically isolating or deleting a number of domains 
of Emi1 for functional testing against APC/C-mediated ubiquitination in vitro.  Utilizing 
recombinantly expressed APC/C and its bona-fide cell cycle substrates, we can 
recapitulate the activities of cellular APC/C and analyze loss or gain of function variants 
of Emi1 in in vitro ubiquitination assays.   
 
 
Expression of Recombinant Emi1-Skp1 Protein Complex in E. coli Cells 
 
 With rough approximations of a regulatory N-terminus, an F-box, a D-box, a 
linker sequence spanning between the D-box and a folded ZBR, and the extreme C-
terminal tail, we made whole domain truncations as described in Table 2-1.  For the sake 
of simplicity, I establish and hereafter utilize motif-specific nomenclature for constructs 
of Emi1, namely N, F, D, L, Z, and T for N-terminus, F-box, D-box, Linker region, ZBR, 
and Tail, respectively.  Therefore Emi1 DLZT contains the latter four domains and does 
not contain the N-terminus or F-box, and so on. 
 
Bacterial expression in Escherichia coli has long been a standard technique for 
promoter-driven protein over-expression due in part to the ease of culture maintenance, 
relative affordability, and robustness of expression.  Therefore all gene constructs were 
initially cloned into a robust expression vector with an N-terminal GST affinity tag.  A 
modified version of pGEX-4T1 (GE Healthcare), with a TEV protease recognition site 
replacement of the Thrombin protease recognition site, was an ideal choice for initial 
protein expression for several reasons.  First, the genetic linkage of Emi1 to a GST tag 
allows for significant improvement in purity from affinity chromatography over the more 
widely use hexa-Histidine tag, and subsequent TEV-mediated liberation of the GST tag 
yields high-quality protein with nearly native amino acid sequence.  This also subverts 
the need for immobilized metal affinity chromatography, which may interfere with 
Emi1’s Zinc-binding region.  Second, the pGEX vector is under control of the Lac operon 
and therefore protein expression is directly induced with a relatively inexpensive 
chemical called isopropyl-thiogalactopyranoside, IPTG.  As such, this vector has been 
widely used to produce high quantities of well-purified protein samples.   
 
For Emi1 constructs that contain the folded F-box motif, dual-plasmid co-
expression with a Skp1 clone was found to be necessary, as uncomplexed Emi1 F-box 
yields very little protein.  Following standard expression and induction protocols, the 
initial quantity and quality of GST-Emi1 produced for these constructs was widely  
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Table 2-1. Emi1 Constructs Are Named According to Their Inclusive Domains. 
 
Construct Residues Skp1 
Coexpression 
Expression 
System 
Emi1-NFDLZT 
(full-length) 
1-447 
 
Yes High-five 
Emi1-NFDLZ 1-432 Yes High-five 
Emi1-NFDL 1-362 Yes High-five 
Emi1-FDLZT 236-447 Yes BL21 Gold 
Emi1-DLZT 305-447 No BL21 Gold 
Emi1-ZT 363-447 No BL21 Gold 
Emi1-T  No Synthesized 
 
Emi1-NFDLZT contains the N-terminus, F-box with Skp1 bound, D-box, Linker 
Domain, Zinc-Binding-Region, and essential Tail residues.  Smaller constructs lack one 
or more of these domains and are named accordingly. 
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variable.  Whereas milligram quantities of pure Emi1-DLZT or ZT are obtained per liter 
of expression, only microgram quantities of relatively impure Emi1-NFDLZT are 
expressed in E. coli, even when co-expressed with Skp1.   
 
 
Expression of Emi1-Skp1 in High-Five Insect Cells 
 
 Notably, constructs containing sequence more N-terminal than the F-box were 
unable to be expressed in bacteria in sufficient quantity for purification.  These clones 
were transferred to a baculovirus-containing plasmid for transfer to an insect cell 
expression system (Philipps, Forstner et al. 2005).   The Bac-to-Bac vector system 
(Invitrogen) allows for viral incorporation of Emi1 genes, and subsequent transfection 
into insect cells in a number of steps.  A plasmid called a Fastbac is first transformed to 
chemically competent cells harboring baculovirus DNA and incorporates the viral DNA 
in a process termed transposition.  Bacmid DNA is then purified from these cells, which 
harbors the Emi1 gene, a reporter GFP, and necessary components to produce live virus.  
Transfection of this bacmid DNA to adherent SF9 insect cells initiates the viral life cycle 
and virus can be harvested in the extracellular medium 3 days post-infection (d.p.i.).  This 
process can be repeated to increase viral titers until mature, concentrated viral media can 
be used to infect large-scale suspension cultures of another insect cell line, High-five 
(Hi5).  Using this expression system, N-terminal Emi1 constructs could be generated in 
sufficient quantity and quality for purification and use in assays (Figure 2-1).  With the 
combination of these two expression systems, high-level overexpression of all Emi1 
constructs is possible, and procedures for purification of these proteins can be developed. 
 
 
Individualized Purification of Emi1 Constructs 
 
 A single, standard purification protocol was applied en bloc to all of these 
constructs, with various outcomes.  While some constructs behaved quite well and were 
readily purified through affinity, ion-exchange (IEX), and size-exclusion (SEC) 
chromatographies, others were unable to be purified in this way for varied reasons.  This 
section will highlight some of the most important observations and the protocols that 
were developed to produce large quantities of optimally pure protein in the most time- 
and cost-effective way for the variety of Emi1 constructs.  
 
 
N-terminal Constructs of Emi1 Are Unstable and Require High Ionic Strength 
 
 Full-length Emi1-NFDLZT as well as constructs containing the N-terminus 
through residue 432 (NFDLZ), or residue 362 (NFDL), were expressed in high-five cells 
as previously described.  These protein complexes (each are co-expressed with Skp1) are 
observed to be relatively unstable and require high ionic strength for solubility.  
Following GST immobilization chromatography, or GST pulldown, overnight dialysis to 
50mM Tris pH 7.6, 50mM NaCl, 5mM DTT resulted in significant precipitation present  
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Figure 2-1. Emi1-NFDLZT Purification on Cation Exchange. 
 
Above, representative gradient elution from Cation Exchange collected in several 5mL 
fractions.  Below, 5µL each fraction under the peak is analyzed for purity and 
concentration on SDS-PAGE. 
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inside the protein-containing dialysis tubing, and insignificant Emi1 protein remaining in 
the soluble fraction.  To overcome this issue, following affinity chromatography these 
constructs are dialyzed and cleaved in a buffer containing 50mM MES pH 6.0, 200mM 
NaCl, and 5mM DTT.  By maintaining physiological NaCl concentration, no 
precipitation is observed, and the slightly basic pH of the MES buffer affords tighter 
binding to cation exchange resin in the next step.  To further enhance the affinity with 
cation exchange resin, gradual dilution to 100mM NaCl while mixing is required and 
immediate cation exchange is used to remove all liberated GST and several other 
impurities.  Protein precipitation is observed at this dilution step on a time-course and 
NaCl dilution titration, necessitating immediate loading to the IEX resin.  Elution with a 
shallow NaCl gradient yields a strong protein peak that correlates with fractions 
containing Emi1 (Figure 2-1).  Following IEX, the protein is further purified and buffer 
exchanged to 20mM Tris pH 7.6, 150mM NaCl through SEC on a 10/300 superdex 
column. 
 
 
Emi1 FDLZT Is Easily Purified in Complex with Skp1  
 
 Despite containing the F-box and Skp1 co-expression like other N-terminal 
constructs, FDLZT (residues 236-447) gives moderately good yield from bacterial 
cultures, and is purified without precipitation or loss of activity using a standardized 
protocol.  Following GST pulldown and glutathione-mediated elution, FDLZT constructs 
are treated with ~1% w/w TEV protease in elution buffer at 16°C.  To enhance binding to 
IEX resin, the protein is diluted four-fold in buffer absent of salt, bringing the 
concentration of NaCl to 50mM.  No precipitation is observed at low NaCl, perhaps 
implicating the N-terminal 235 residues of Emi1 in NaCl-dependent solubility.  
Following elution from cation exchange by a NaCl concentration gradient, the protein is 
further purified through SEC, concentrated to ~100µM and flash-frozen in liquid nitrogen 
for storage at -80°C.  
 
 
The C-terminal Inhibitory Region of Emi1 Requires Optimization of Purification 
Protocols 
 
 Emi1-DLZT and ZT protein purification are performed similarly to FDLZT 
through GST-affinity chromatography.  However, glutathione-mediated elution is 
inefficient and requires up to 20 CV before Emi1 is fully removed from the column.  The 
massive volume of eluent is problematic for downstream purification procedures, and is 
unable to be concentrated despite several hours of centrifugal pressure in a centrifugal 
concentrator.  To first identify the underlying biophysical events causing these problems, 
glutathione eluent protein samples were loaded to an Ethidium Bromide (EtBr) agarose 
gel typically used for purification of nucleotide products.  Indeed, Emi1 DLZT purified 
from BL21 cells and purified through GST affinity is visible through EtBr staining 
suggesting the protein sample forms intermolecular crosslinks with nucleotides.  Due to 
these non-specific crosslinks, elution from all types of sepharose columns is impractical 
and leads to damage and clogging of columns and concentrating membranes.  Following 
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subsequent cation exchange, fractions from the IEX unbound and wash pools contain 
nucleotides, whereas protein eluate does not stain with EtBr (Figure 2-2).  
 
 To overcome this, multiple approaches were attempted simultaneously.  Inclusion 
of DNAse had negligible effect when added either to the lysis or elution buffers, and 
purifications performed in 1M NaCl yield half the protein but do not positively affect the 
glutathione elution profile (Figure 2-3).  Though on-column cleavage is typically 
avoided to prevent enzymatic contamination of resins and columns used in future 
purifications, it was tested as an alternative to glutathione elution for these constructs.  
An improvement in elution was not expected, as the GST-tag itself is not implicated as 
the problem and Emi1 would still be capable of association with nucleotides as before.  
Much to our surprise, on-column cleavage with TEV allowed for liberated Emi1 to elute 
from the column in only 2 column volumes, making four-fold dilution of NaCl in 
downstream steps non-prohibitive. Furthermore, by leaving the liberated GST tag on the 
column, the eluent of on-column cleavage is nearly full-purity Emi1 (Figure 2-4).  To 
remove the small amount of remaining impurities, we further purify by cation exchange 
using free resin in batch and transferring to gravity columns.   
 
A combination of factors makes this purification protocol scalable to both high 
and low number of constructs, at high or low culture volume; a single construct of 24 
Liters of cells yields protein of similar quality to multiple constructs at 1 Liter scale with 
similar demands on time and technical performance.  By performing purification steps 
manually in plastic columns instead of through automated FPLC runs, many constructs 
are simultaneously purified, and eluted samples do not require time-consuming 
centrifugal concentration steps prior to IEX as they are robustly expressed and eluted at 
small volumes.  This protocol makes it possible to purify upwards of 60 different 
constructs of Emi1-DLZT, Emi1-FDLZT or full-length Ube2s at 1 Liter scale within 48 
hours by a single person (Figure 2-5).  This provides the framework for development of 
mutagenesis experiments that require multiple variants of a single Emi1 construct at 
approximately equal purity.  Following functional assay screens of the many mutants 
purified this way, protein constructs with desired behaviors can be followed up by larger 
scale purification ending in SEC for final polishing and full purification.  
 
 
Utilizing Assays That Segregate the Functions of the APC/C-specific E2s Ubch10 
and Ube2s 
 
 In order to be able to test Emi1 function, we utilize established in vitro 
ubiquitination assays in a variety of ways.  By modifying pure proteins with fluorescent 
markers, we can monitor the ubiquitination of APC/C substrates in fluorescent scans of 
SDS-PAGE gels as slower-migrating (and therefore more modified) species.  For the 
majority of assays presented in this work, we have chosen an N-terminal fragment 
containing the N-terminal 95 residues of Cyclin B.  This construct contains several 
lysines for modification with Ubiquitin, and behaves well as an in vitro substrate in 
published studies (Dimova, Hathaway et al. 2012). Ubiquitination assays are performed  
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Figure 2-2. Emi1-DLZT Dissociates from Nucleotides during IEX. 
 
Protein samples are loaded to 0.8% agarose gel and stained with EtBr.  Lane 1 contains 
GST-Emi1-DLZT elution from GST-pulldown, Lane 2 contains product of TEV 
cleavage, Lane 3 shows the unbound fraction from ion exchange, and Lane 4 shows pure 
Emi1 protein eluent from ion exchange. 
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Figure 2-3. Increased Ionic Strength and DNAse Treatment Do Not Prevent 
Nucleotide Binding. 
 
DNAse and 1M NaCl concentration each fail to clear nucleotides from Emi1-DLZT 
protein preps.  With protein elution requiring many column-volumes (CV), downstream 
purification steps are impossible. 
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Figure 2-4. On-column Cleavage Effectively Purifies Emi1-DLZT from GST in 
Small Volumes. 
 
On-column cleavage is performed for Emi1-DLZT and protein products are visualized by 
SDS-PAGE.  Lane 1 contains the first column-volume elution using wash-buffer, Lane 2 
contains the fifth column-volume elution using wash-buffer, and Lane 3 contains the first 
column-volume elution with Glutathione.  This suggests Emi1 is completely liberated 
from GST, is eluted in low volume, and is well-purified from GST or contaminants 
following wash-buffer elution.  Wash-buffer contains 50mM Tris pH 7.6, 200mM NaCl, 
5mM DTT, and no Glutathione. 
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Figure 2-5. Optimized Purification Strategy Yields Pure Ube2s and Emi1. 
 
Optimized purification of Ube2s (Top), Emi1-DLZT, (Bottom), or Emi1-FDLZT-Skp1 
enables preparation of 60 constructs purified to high quality at the same time.  This 
purification strategy makes Tryptophan-, Alanine-, and Amber-Scanning Mutagenesis 
experiments possible at large scale.  
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by combining two independent mixtures: one contains APC/C, 5 mM MgCl2, 5 mM 
ATP, 0.25 mg/mL BSA, 1µM Cdh1, and 100 nM UBA1, and the second mixture contains 
E2, 125µM bovine Ubiquitin (Sigma) and fluorescent substrate.  APC/C in the first 
mixture is incubated with Cdh1 on ice for at least 30 min prior to mixing. This 
combination prevents autoubiquitination of the E2 enzyme, which occurs when the E2 is 
capable of loading but does not have a substrate to target (Jarvis, Brown et al. 2016).   
 
 The APC/C works with two distinct E2s in a sequential manner.  The requirement 
for the substrate to be ubiquitinated before Ube2s can function makes it difficult to 
segregate any E2-specific functions of Emi1 inhibition.  To circumvent this problem, a 
Ubiquitin protein is genetically fused to the N-terminus of Cyclin B 1-95 (UbCyclin B) 
that is labeled and purified as before.  This mimic of ubiquitinated Cyclin B bypasses the 
requirement for the initiating E2, Ubch10.  Therefore assays separating the functions of 
each E2 can be tested in Emi1 inhibition assays. 
 
 After establishing baselines for APC/C activity along a timecourse, Emi1 can be 
tested as an inhibitor of APC/C function.  Emi1 is added to the mixture containing 
APC/C-Cdh1 and allowed to incubate 1 hour before starting the reaction with E2 and 
substrate.  This allows complexes of APC/C-Cdh1-Emi1 to form at equilibrium 
regardless of the affinity of mutant versions of Emi1.  Emi1 is a potent inhibitor of 
APC/C-Cdh1 mediated ubiquitination of the fluorescent Cyclin B 1-95 either with 
Ubch10 or Ube2s alone (Figure 2-6).  This provides the first evidence that Emi1 may be 
acting as a general APC/C inhibitor and not targeting the individual functions of the E2s.   
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Figure 2-6. Emi1 Is a Potent Inhibitor of APC/C Mechanism in Assays That 
Segregate Both E2 Enzymes. 
 
Fluorescent scan of SDS-PAGE results of ubiquitination assays monitoring fluorescent 
substrate modification by APC/C in presence or absence of Emi1-FDLZT.  
Ubiquitination of Cyclin B 1-95* by Ubch10, Left, and Ub~Cyclin B 1-95* by Ube2s, 
Right, are both inhibited by 50nM Emi1-FDLZT in a 12-minute reaction containing 
12.5nM APC/C-Cdh1.  
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CHAPTER 3.    MAPPING THE DOMAINS WITHIN EMI1 THAT 
CONTRIBUTE TO APC/C INHIBITION 
 
 
Introduction to Emi1 as a Multi-Modal Inhibitor 
 
Three essential motifs and domains of the Emi1 protein have been discovered 
prior to this study, and provide a basis for understanding Emi1 activity and for our 
thorough biochemical characterization.  Critical to Emi1’s proposed mechanism is a 
canonical D-box degron motif.  This motif is commonly found in APC/C substrates and 
represents the major mode of substrate recruitment and targeting.  The relative simplicity 
and disordered nature of the D-box motif presents a conundrum for APC/C substrate 
recruitment: conceivably many proteins contain Arginine-x-x-Leucine (RxxL) sequences, 
but are not intended APC/C targets.  Indeed, Emi1 itself has two such sequence motifs 
and is predicted to be largely intrinsically disordered, fulfilling the two requirements for 
D-box binding.  In preliminary studies, mutation of the conserved D-box of recombinant 
human Emi1 (Ala322-x-x-Ala325) reduces immunoprecipitation of APC/C from HeLa 
extracts (Reimann, Gardner et al. 2001) and does not sustain M-phase arrest in the 
Xenopus laevis meiotic homolog Erp1 (Ohe, Inoue et al. 2007, Tischer, Hormanseder et 
al. 2012). 
 
The same studies introduce a Zinc-dependent folded domain which is similarly 
conserved in Emi1 and Emi2.  This domain, called the Zinc-Binding Region (ZBR) 
coordinates two zinc ions using 8 conserved Cysteine and Histidine residues.  Metal ion 
coordination is often a requirement for structural integrity within these types of domains, 
and this is evidenced for Emi1 by loss of function in Emi1 proteins mutated for one of the 
conserved zinc-coordinating Cysteine residues (Miller, Summers et al. 2006).  Similarly, 
removal of Zinc itself with a specific chelator, TPEN, abrogates Emi1 function, which 
can be rescued by addition of excess Zinc (Reimann, Gardner et al. 2001).  These results 
suggest that Emi1’s ZBR domain is either capable of a folding-unfolding transition that is 
dependent on Zinc, or participates in metal-dependent catalytic mechanism.  Either may 
provide a mechanism for sensing cellular cues or localization-dependent regulation of 
Emi1 function. 
 
Emi1 D-box and ZBR domains were its first functional elements to be discovered, 
and are both evolutionarily conserved and retained within functional homologs of Emi1.  
Closer inspection of the data characterizing these regions does not account for the full 
capacity of Emi1, however. A third conserved, functional element was later speculated to 
account for these discrepancies.  At the extreme C-terminus of Emi1 and homologs is a 
so-called RL tail consisting of a penultimate Arginine and C-terminal Leucine.  In studies 
of both Emi1 and Emi2, deletion or Alanine substitution of these residues prohibits 
association with APC/C as detected in immunoprecipitation experiments in human 
embryonic kidney cells (Ohe, Kawamura et al. 2010). 
 
The preliminary data generated in these studies suggest that Emi1 requires a 
variety of motifs for function, but the mechanism of inhibition is still unknown.  
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Wholesale deletion or mutation of critical domains in Emi1 makes it a defunct inhibitor, 
but neither the loss-of-function nor the wild-type mechanism is convincingly explained.  
Having overcome the technical hurdles of expressing both active APC/C-Cdh1 and a 
variety of Emi1 constructs recombinantly, and with ubiquitination assays that segregate 
the functions of the APC/C’s E2 enzymes, studies characterizing and ranking the diverse 
modalities of Emi1’s domains can be performed.  Our in vitro ubiquitination system does 
not have the limitations associated with experiments performed in cells or lysates.  The 
purified system both increases the capacity for experimentation and reduces the 
complexity of result analysis.  With this toolbox of techniques and knowledge, we are 
well equipped to study mechanism and structure of Emi1 inhibition of the APC/C.   
 
The N-terminus of Emi1 has been implicated in Emi1’s own regulation through 
phosphorylation, association with CRLs, and subsequent destruction, though it is not 
clear whether it is required for APC/C-specific activity.  To isolate regions of Emi1 that 
are critical for APC/C inhibition, constructs are designed with wholesale deletion of a 
variety of Emi1 domains.  We first establish that constructs that delete either 235 residues 
or 304 residues (FDLZT, DLZT) from the N-terminus are equally potent inhibitors to 
full-length Emi1-Skp1 in qualitative assays.  In agreement with previous studies, 
constructs which impinge on either the Dbox (residues 322-325) or the extreme C-
terminus (residues 444-447) are deficient suggesting that approximately residues 300-447 
represent the minimal Emi1 construct that exhibits wild-type activity (Frye, Brown et al. 
2013). 
 
 
Alanine Scanning Mutagenesis of the Conserved Zinc-binding Region of Emi1 
 
As the name suggests, Emi1’s ZBR domain has been shown to bind Zinc and this 
metal coordination is in some way important for Emi1’s function.  To further characterize 
the structural requirement for this domain, I developed an alanine scanning mutagenesis 
experiment.  Many clones harboring single, double, or triple amino acid substitutions 
were prepared by site-directed mutagenesis.  The structure of the folded ZBR was 
recently determined in our lab through NMR experiments, allowing selective mutation of 
only surface-exposed residues which would be candidates for intermolecular interactions.  
By mutating surface residues that are presumed not to be necessary for the overall fold of 
the ZBR, we can determine if any one residue or set of residues are important for binding 
and inhibiting the APC/C.  
 
 
Selective Mutant Emi1 Proteins Exhibit Deficiency for APC/C Inhibition in an E2-
independent Manner 
 
To be thorough our mutational analysis includes 27 mutations covering the entire 
surface of the ZBR, a 45-residue domain, and these mutations were cloned in duplicate to 
Emi1-FDLZT and Emi1-DLZT to eliminate spurious effects and false-positives.  We first 
utilize assays with Ubch10 and APC/C catalyzing ubiquitination of Cyclin B with 
titrations of WT Emi1 inhibitor to determine a sensitive range for inhibition.  Within this 
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range, Emi1 concentrations allow near-complete inhibition of APC/C activity, but are not 
in excess such that subtle defects are compensated for.  Many features of ubiquitination 
assays are malleable, especially timecourses and relative enzyme/substrate 
concentrations.  These parameters are systematically altered to find the optimal 
conditions to visualize real defects in Emi1 inhibition. 
 
Following assay optimization, purified Emi1-DLZT mutant proteins are screened 
for potency at two concentrations, 300nM and 60nM.  Although the majority of mutant 
Emi1 proteins are efficient inhibitors, defects are observable for 9 clones and are colored 
according to rank-order (Figure 3-1).  Prompted by these results, we designed 
experiments to test whether the defects observed for Emi1 inhibition of this Ubch10 
assay would persist for Ube2s.  It is conceivable that the Emi1 ZBR somehow blocks 
Ubch10 activity or association with the APC/C, but does not affect Ube2s.  This 
hypothesis is supported by unpublished data suggesting that Ube2s utilizes distinct 
surfaces of the Cullin-RING machinery within APC/C for its function.  In this scenario, it 
is also possible that the mutations causing defects for Ubch10 would be benign in a 
Ube2s assay, read out as wild-type inhibition capacity.  To test this directly, we utilize 
UbCyclin B which bypasses Ubch10 as previously described, and monitor Ube2s-APC/C 
mediated ubiquitination.  As before, the assay is optimized with wild-type Emi1 to 
establish the same sensitive range for inhibition. 
 
Surprisingly, Emi1 surface mutations that render it inefficient at inhibiting 
Ubch10 have the same effect for Ube2s.  There are two logical explanations for this 
result: either the mutations disrupt the folding of the ZBR domain, or they suggest that 
Emi1’s ZBR contributes globally to inhibition of the catalytic mechanism of the APC/C, 
not necessarily interrupting either E2 interaction specifically.  To gain insights about the 
ZBR fold respective to these deleterious mutations, HSQC NMR experiments were 
performed on purified Emi1-ZT wild-type and mutant proteins.  We were able to disavow 
mutation R393/T395 in the middle of a hydrophobic Beta-sheet through this screen, but 
other defective mutants exhibit the hallmarks of native ZBR folding, namely L375A and 
K376A (data not shown).  This affirms that surface residues of Emi1 ZBR that are not 
required for native tertiary structure formation are important for APC/C inhibition. 
 
Discovering a Single Surface of the Emi1 ZBR That Mediates Activity 
 
The residues defective in our ZBR Alanine scan are distant in primary sequence space, 
ranging from L375 to L410.  However, when studying the NMR structure, these residues 
localize to a single surface within the folded domain.  This provides evidence that one 
surface of Emi1’s ZBR domain mediates contact with the APC/C either through inter- or 
intra-molecular interactions (Figure 3-2).  Performing the entire screen again using 
Emi1-FDLZT-Skp1 further validated these results.  The same ZBR mutant residues 
perturb Emi1 activity in proteins from a different construct and clonal source, confirming 
there is no experimental or systematic error with the proteins or the assays. 
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Figure 3-1. Alanine Scan of Emi1’s ZBR Reveals Amino-acids Required for 
Function. 
 
Ubch10-mediated ubiquitination of Cyclin B 1-95* is inhibited by 60nM Emi1-DLZT.  
Some mutations of Emi1 at the indicated positions hinder this function.  Magenta circles 
indicate strongly deficient mutations, and orange circles indicate mildly-deficient 
mutations. 
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Figure 3-2. Alanine Scanning Mutagenesis Reveals a Single Surface Required for 
Inhibition. 
 
Cartoon representation of the ZBR domain of Emi1 with results from Alanine scanning 
mutagenesis experiments highlighted in magenta (very deficient), or orange (mildly 
deficient). Mutants containing R393A have not been colored magenta, as they do not 
report on APC/C inhibition.  Side-chains are shown in gray for all mutations in the screen 
that were not deficient in APC/C assays. 
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Discovery of an Essential Linker Domain Between Emi1’s D-box and ZBR Domains 
 
Both the ZBR and the D-box were implicated in previous studies as functionally 
relevant motifs of Emi1, described above.  Again utilizing our in vitro expression and 
assay system, mutations of Emi1’s D-box can be tested in the context of Emi1’s 
inhibitory C-terminus.  The Arg322-x-x-Leu325 mutation to Ala-x-x-Ala characterized as 
D-box dead is in fact required for Emi1 function, but not to the extent suggested from 
immune-precipitation experiments found in literature (Reimann, Gardner et al. 2001, 
Miller, Summers et al. 2006).  This mutant, hereafter Dmut is less harmful than mutation 
of the ZBR in a single assay (Figure 3-3, lanes 2, 3, 4, 13).  A wholesale deletion of the 
D-box in a construct retaining both wild-type ZBR and the RL tail (Emi1-ZT) does not, 
however, mimic the simple D-box mutation.  This completely unexpected result leads us 
to consider other differences between Emi1-DmutLZT and Emi1 ZT.  We hypothesize that 
there may be a functional motif in the linker domain which connects Emi1’s D-box to the 
ZBR.  Functionality of this previously undiscovered region would rectify the disparity in 
Emi1 activity between our mutants, as it is left intact in Emi1-DmutLZT, and deleted in 
Emi1-ZT.   
 
 
Wholesale Deletion of a Linker Region of Emi1 Reveals a Functional Requirement 
for This Region 
 
To test this hypothesis, systematic deletion mutants targeting neither the D-box 
nor ZBR, but specifically the previously benign Linker domain between them were 
designed and prepared.  We begin with a relatively mild deletion of 5 residues in the 
approximate center of this Linker domain, and further extend deletions in both directions 
to a total deletion of 10, 20, or 30 residues of this 50-residue sequence (Figure 3-3, top).  
Both Ubch10 and Ube2s-specific assays present identical functional consequence of 
Emi1 Linker deletion:  10-residue deletions are tolerated well in these assays, while 20- 
and 30-residue deletions render Emi1 functionally incompetent.  Importantly, both the D-
box and ZBR domains are intact in these constructs, pointing to a novel functional 
requirement for Emi1 inhibition. 
 
 
Residues Within Emi1’s Linker Region Are Required for Inhibition 
 
Two possible scenarios account for this unexpected but striking result:  either 
there are specific amino acids in this Linker region which are mediating contact with 
APC/C, or the distance spanned by these ~40-50 amino-acids is important to allow 
simultaneous D-box recruitment and ZBR engagement.  Much of Emi1 is predicted to be 
intrinsically disordered, potentially to maximize the distance achievable with limiting 
sequence space.  To test first whether only distance is required, I supplant the defective 
20-residue deletion with 20 inherently flexible and extended Glycine, Serine, and 
Threonine residues.  This full-length but mutant sequence of Emi1 does not robustly 
compensate for the 20-residue deletion, suggesting a functional role of specific amino- 
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Figure 3-3. Relative Analysis for Mutations of Emi1 D-box, ZBR, and Functional 
Linker Domain Between Them. 
 
Top, protein sequence and domain representation for Emi1 D-box and Functional Linker 
domain.  Mutations in this region are annotated on the left, and color-coded for clarity.  
Bottom, fluorescent scan of SDS-PAGE results from inhibition of APC/C-Ubch10-
mediated ubiquitination.  Emi1-DLZT mutant proteins, as ascribed, are tested for their 
ability to inhibit Cyclin B 1-95* ubiquitination by APC/C. 
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acid side-chains in this region.  In other words, since the distance can be spanned again, 
but the defect still exists, it is likely that the amino-acid side-chains in this region are 
important.  Multiple lines of evidence further support this hypothesis.  Firstly, knowing 
that a 10-residue deletion behaves normally where a 20-residue deletion is severely 
deficient, I hypothesize that any sequence-specific functionality would derive from the 
opposite 10 residues (termed V2 for version 2) which are further deleted to form the 20-
residue deletion construct.  In the same assay, the first 10-residue deletion behaves 
normally, where an orthogonal 10-residue deletion is severely deficient. Secondly, we 
locate specific residues within the linker that contribute to Emi1 activity.  In the context 
of both the full-length-native, and benign 10-residue mutations, I make substitutions for 
patches of residues in the offending 10-residue Linker sequence.   Triply mutating 
conserved Leu345, Tyr356 and Arg358 to Alanine residues was sufficient to substantially 
impair inhibition.  Upon closer inspection of the data, mutation of these three residues 
alone, in otherwise wild-type Emi1-DLZT, prevents Emi1 inhibition to a similar degree 
as Emi1-DmutLZT and the Emi1-DLZT ZBR mutant (C409A, Figure 3-3, bottom).  
Therefore in these experiments, the contribution towards Emi1’s mechanism is 
approximately equal for each of these 3 domains. 
 
 
Emi1 Contains a Relatively Weak D-box and an Essential RL-Tail 
 
 
Strengthening Emi1’s Pseudosubstrate Activity Through Fusion with the D-box 
Region of Hsl1 
 
At least four domains, then, contribute to Emi1 activity: a D-box, a folded ZBR, a 
functional Linker between them, and a conserved RL Tail.  To further characterize the 
relationship between these domains, and describe if they work competitively or 
cooperatively, we design constructs to enhance one domain and look for compensation of 
mutations in other domains.  Emi1’s D-box contributes the least to inhibition, evidenced 
by the relatively good inhibition of Emi1-DmutLZT in Figure 3-3, lane 4.  We tested this 
directly by generating peptides corresponding to the isolated D-box of both Emi1 and 
another D-box containing protein, the yeast APC/C substrate Hsl1.  In isolation, Emi1’s 
D-box is inefficient at blocking substrate ubiquitination, whereas an isolated peptide of 
Hsl1 potently blocks Cyclin B recruitment to the APC/C, presumably as a competitive 
inhibitor of the D-box binding site between Cdh1 and APC10 (Figure 3-4).  Based on 
this information, a chimeric Emi1~Hsl1 fusion protein is generated that replaces the 
relatively poor sequence flanking and including the Emi1 D-box with the analogous 
region from Hsl1.  This enhanced D-box version of Emi1, hereafter Super D-box or 
SuperD, is a much more potent inhibitor and nearly overcomes Emi1’s requirement for 
either a Linker or a ZBR (Figure 3-3, lanes 12, 13).  Though we can only explain the 
mechanism but not the purpose for an avidity requirement, our analysis reveals that Emi1 
has evolved to utilize multiple weak motifs throughout the span of its C-terminus, which 
are each essential but not sufficient for inhibition.   
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Figure 3-4. Emi1 D-box in Isolation Is an Inefficient Inhibitor of APC/C. 
 
Left, Schematic Diagram and Sequence Information for D-box peptides generated for 
Emi1 and Hsl1.  Hsl1 sequence in red directly replaces analogous Emi1 sequence above 
it in SuperD constructs.  Right, Emi1 D-box peptide is tested for inhibition of Cyclin B 
1-95* ubiquitination by APC/C-Ubch10 alongside Hsl1 D-box peptide.   
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Emi1’s C-terminal RL-Tail Inhibits Ube2s Specifically 
 
 Emi1 terminates with a Leu-Arg-Arg-Leu Tail (LRRL, or RL-tail) that is 
conserved both throughout evolution and among homologs (Figure 3-5).  Our analysis 
has so far characterized the contributions of Emi1’s D-box, Linker, and ZBR domains as 
weak but cooperative for binding and inhibiting APC/C activities.  Constructs of Emi1 
deleted for the C-terminal Tail domain were inefficient inhibitors in data not shown, 
which is in accordance with published data suggesting a role for the Tail in APC/C 
recruitment (Ohe, Kawamura et al. 2010).  To study this domain’s contributions, then, we 
generate the Tail domain in isolation through peptide-synthetic chemistry.  Despite the 
isolated Emi1-T being a significantly weaker inhibitor of the APC/C, at high 
concentrations this small peptide is capable of inhibiting specific APC/C functions, 
described below. 
 
 Close inspection of the C-terminal extension of one of the E2 enzymes specific 
for APC/C polyubiquitination, Ube2s, reveals similar distinguishing features.  For 
instance, an extended, unique basic tail follows the structurally conserved globular core 
domain shared among E2s.  This Lys-rich E2-tail also terminates with an identical LRRL 
motif (Figure 3-5) that is not found in Ubch10.  We hypothesize that Emi1 could 
antagonizes the activity of Ube2s, but not Ubch10, through direct competition for APC/C 
binding sites.  We test this in a battery of Ubch10 and Ube2s specific assays, as well as 
ubiquitination assays which utilize both E2s and more directly recapitulate the in vivo 
function of the APC/C.  What is clear from our results is that Emi1-T is a specific 
inhibitor of Ube2s-directed polyubiquitination.  In a representative assay incorporating 
the activity of Ubch10 and Ube2s together, a titration of Emi1-ZT selectively inhibits 
Ube2s’s Ubiquitin-extension mode of action (Figure 3-6).  Qualitatively, no decrease in 
Ubch10-derived ubiquitination is observed (visualized as lower molecular-weight 
conjugates of 1 to 4 Ubiquitin proteins).  Higher molecular-weight species, which are 
produced by Ube2s modification of Ubch10’s products, are specifically inhibited upon 
titration of Emi1’s isolated Tail.  Conceptually, if Emi1-ZT were a Ubch10-specific 
inhibitor, we would expect that any low-MW conjugates would be efficiently 
polyubiquitinated and the migration pattern observed would be significantly different.  
This discrete function of Emi1 is corroborated in other in vitro assays (Wang and 
Kirschner 2013) monitoring radiolabeled Securin modification in the presence of Emi1 
containing or lacking the C-terminal RL tail. 
 
 
Visualizing an APC/C-Cdh1-Emi1 Complex Through Electron Microscopy 
 
Our biochemical studies provide a comprehensive understanding of how Emi1 
interacts with the APC/C through several domain contacts, utilizing a multimodal 
framework for inhibition.  Evidence suggests that the Emi1 D-box engages the D-box co- 
receptor proteins Cdh1 and APC10 in the top of the catalytic core, in the same way that 
substrates have been visualized in previous studies (Passmore, McCormack et al. 2003, 
Carroll, Enquist-Newman et al. 2005, Buschhorn, Petzold et al. 2011).  Our 
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Figure 3-5. Emi1 C-terminal Tail Is Conserved Throughout Evolution, Among 
Homologs, and with Ube2s.  
 
Schematic diagram and sequence information is shown for C-terminal tail of Emi1.  
Alignment of Emi1 from Humans, Frogs, and Zebrafish, Human Emi2, and Human 
Ube2s reveal a conserved LRRL tail.  
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Figure 3-6. Emi1-ZT Inhibits Ube2s-generated High Molecular Weight Products. 
 
Cyclin B 1-95* modification by APC/C with both Ubch10 and Ube2s is monitored in the 
presence of selected Emi1 variants.  A titration of Emi1-ZT reveals selective inhibition of 
high molecular weight products. 
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characterization of a Linker and ZBR domain suggest that Emi1 is somewhat flexibly 
tethered to the APC/C through several important contacts, but is not spanning the 
maximal distance afforded by the sequence of Emi1.  What is still entirely unknown, with 
the exception of the assumed D-box recruitment mechanism, is how and where these 
domains are binding to the APC/C.  Though Emi1-T competes for Ube2s recruitment, 
and Emi1 ZBR affects catalytic efficiency, global placement of these domains is 
impossible with current structural information.  Prior to this study, years of APC/C 
structural characterization revealed the approximate locations of a majority of APC/C 
proteins within the complex.  Notably, the APC2-APC11 Cullin-RING proposed catalytic 
machineries have not been visualized as they are likely not rigidly attached to the body of 
the complex.  If APC2 and APC11 behave similarly to other CRL family members, there 
are likely mobile elements that make their contributions to the averaged electron density 
map insignificant.  It is believed that APC2 and APC11 function within the so-called 
catalytic core in the middle of the APC/C where the D-box co-receptors tether substrates.  
Studies of the MCC support this hypothesis, as the much larger inhibitory complex is 
shown to compete for the APC/C core and block APC/C activity through steric hindrance 
(Herzog, Primorac et al. 2009).  We aim to visualize the structure of Emi1 bound to 
APC/C through electron microscopy to localize the sites of intermolecular contacts and 
understand more about the mechanism of inhibition.  In collaboration with the Stark lab 
at the Max Planck Institute for Biochemistry in Göttingen, Germany, we perform EM 
studies to visualize our recombinant APC/C as an apoenzyme or in complex with Cdh1 
and Emi1.  
 
 
Insertions of Globular Domains Reveal Emi1 Position and Orientation on the 
APC/C 
 
EM analysis reveals that despite its small size, Emi1-DLZT spans much of the 
central core of the APC.  In order to map the location of C-terminal elements of Emi1, we 
purify Emi1-FDLZT-Skp1 proteins that have been engineered with large propeller 
insertions near specific domains within Emi1’s C-terminal inhibitory region.  These 
proteins were monitored closely throughout purification for behaviors either consistent 
with Emi1-NFDLZT, Emi1-FDLZT, or Emi1-DLZT so the purification strategy could be 
tailored to account for the insertions.  Despite the large insertion nearly doubling the size 
of our GST-Emi1-FDLZT construct, the purification protocol was indifferent and 
proteins were purified to high quality using the standard Emi1-FDLZT protocol (Figure 
3-7).  
 
APC/C samples with Emi1 bound were prepared by Georg Petzold in Jan-Michael 
Peters lab, and Holger Stark calculated single-particle EM reconstructions for  all 
samples, including mutants in Emi1-FDLZT-Skp1 with insertions between residues S354 
and T355 in the Linker and following the C-terminal LRRL Tail.  Since the C-terminal  
tail is required for maximal complex formation, the SuperD version of Emi1-FDLZT-
Skp1 was necessary.  The insertions contained the Beta propeller from S. cerevisiae 
Doa1, (Pashkova, Gakhar et al. 2010) which is an ideal choice for two reasons.  Doa1’s 
Beta propeller has its N and C termini in close proximity and therefore only minimally  
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Figure 3-7. Emi1-FDLZT-Skp1 with Doa1 Insertions Are Purified Well Despite 
Their Relatively Large Size 
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disrupts structural features of Emi1, and relatively large features such as Beta-propeller 
folds are easily visualized as prominent density in EM.  Although we cannot be certain 
that the insertions do not alter native interactions, our resulting structures suggest an 
orientation of Emi1 that agrees with biochemical data.  The data are consistent with the 
linker projecting away from the D-box bound to Cdh1 and APC10 and toward the APC/C 
platform and catalytic core and with the ZBR and tail extending across the platform to the 
base of the APC/C (Figure 3-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8. Difference Maps for Emi1-FDLZT-Skp1 Containing Beta-Propeller 
Insertions in the Linker Domain and C-terminus. 
 
Density corresponding to the Doa1 Beta-propeller insertions is clear and are colored for 
reference.  Difference density visible from insertion between residues S354 and T355 is 
colored blue, and C-terminal insertion density is colored magenta. 
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CHAPTER 4.    MAPPING EMI1-APC/C AND UBE2S-APC/C INTERACTIONS 
THROUGH BPA PHOTOCROSSLINKING 
 
 
Introduction to Photocrosslinking as a Strategy for Mapping Transient Protein-
Protein Interactions 
 
In the previous sections we both revealed functionally important motifs and 
domains of Emi1, and visualize Emi1 directly binding in the catalytic core of the APC/C 
through electron microscopy.  Emi1 is tractable for EM studies with APC/C due to its 
high-affinity, avid binding.  Studies of this nature are not possible for proteins that 
interact with APC/C more transiently.  Alternate methods must be developed to study the 
nature of this type of interacting protein, and for this we turned to photoactivatable 
crosslinking.   
 
Prompted by new structural and biochemical information from our studies of 
Emi1-bound APC/C, we asked a second related question:  Where does the E2 enzyme 
Ube2s bind to the APC/C?  Ube2s is speculated to behave in a unique way with the 
APC/C.  It does not require the canonical E2-interacting surface of the APC11 RING, and 
does not require interaction with a RING at all to stimulate Ubiquitin transfer (Brown, 
Watson et al. 2014).  How it coordinates with the APC/C to polyubiquitinate substrates, a 
process that is essential for proper mitotic progression (Garnett, Mansfeld et al. 2009, 
Bremm and Komander 2011), is unknown.  We developed an orthogonal crosslinking 
approach to study the interaction of Ube2s with the APC/C.  By allowing recombinant 
Ube2s to interact with APC/C and snap-crosslinking, we can trap the native interactions 
as they occur, even if only transiently. 
 
 
para-Benzoyl-phenylalanine (BPA) Photo-crosslinker 
 
With the end-goal of locating Ube2s points of contact with the APC/C, thus 
giving the first glimpse at its location during ubiquitin chain-elongation, we selected a 
short-range, photoactivatable, non-specific crosslinker called para-Benzoyl-
phenylalanine (hereafter BPA)(Chin, Martin et al. 2002).  This benign crosslinker can be 
introduced to proteins in place of any standard amino acid using a variety of published 
methodologies (Chin, Santoro et al. 2002, Chin, Cropp et al. 2003, Chin, Cropp et al. 
2003, Deiters, Cropp et al. 2003), and is called an Unnatural Amino Acid (UAA).  
Because the crosslinker is inactive until triggered with light, protein-protein interactions 
occur natively, allowing Emi1 or Ube2s to transiently associate with APC/C through 
normal contacts.  Upon excitation with intense UV light at a specific wavelength 
(365nM), the crosslinker’s chemistry allows for short-range nucleophilic attack of 
incompletely identified chemical targets on contacting protein (Yeh, Tung et al. 2016) or 
DNA (Pendergrast, Chen et al. 1992) molecules.  Its usefulness in capturing protein-
protein interactions has been demonstrated a number of times (Liu, Mack et al. 2008, 
Lee, Dimla et al. 2009, Chatterjee, Guo et al. 2013, Brown, Watson et al. 2014, Furman, 
Kang et al. 2014, Javahishvili, Manibusan et al. 2014), and we set out to develop 
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strategies for incorporation of BPA to Emi1 and Ube2s and subsequent crosslinking to 
APC/C-Cdh1. 
 
 
Considerations for Substitution of a Photocrosslinker in Place of Native Amino 
Acids 
 
Some important considerations were made before deciding that BPA crosslinking 
is an appropriate strategy for our system.  Firstly, by replacing a standard amino acid with 
a non-native residue, we might disrupt the overall fold of the target protein and therefore 
lose function.  Secondly, by adding an exceptionally large amino acid analog to the 
proposed interface of a protein-protein interaction, it is possible that the interaction would 
be lost entirely.  Therefore before expending a large amount of effort and time on 
incorporation protocols, we developed a simple screen to mimic the large size of the 
molecule and the effects it might have on our proteins and their intermolecular 
interactions.   
 
 
Development of Methods for Incorporation of BPA to Proteins  
 
 
Tryptophan Scanning Mutagenesis  
 
Using the standard amino acid Tryptophan, which we consider is the best natural 
residue mimic of BPA’s bulky size, we first test the effects of having a BPA molecule 
within proteins.  Using site-directed mutagenesis, a number of desired positions of BPA 
(known or speculated interacting residues on Emi1 and Ube2s) were replaced by 
tryptophan, protein was prepared, and assays for fold or function were employed to 
remove any poorly designed positions.   
 
As a representative assay, Emi1 C-terminal residues 440-447 were mutated to 
Tryptophan and purified as previously described.  Some of these mutants are deficient in 
APC/C inhibition (Figure 4-1), due to disruption of necessary APC/C contacts.  Residues 
that are not contributing to inhibition (Figure 4-1, green indicators) tolerate Tryptophan 
mutations, and are suitable targets for BPA incorporation.  In our scan, residues K442, 
N443, and R445 and an additional residue past the C-terminus, *448, are good candidates 
for replacement with a bulky BPA molecule.  These mutants are in direct agreement with 
an Alanine scan performed in 2010 on Emi2 (Ohe, Kawamura et al. 2010).  The 
analogous Emi1 residue for each of their mutants which are considered defective for 
APC/C association by co-immunoprecipitation experiments is also found to be defective 
in our screen. 
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Figure 4-1. Emi1 C-terminal Tail Residues Are Mutated to Tryptophan to Mimic 
BPA Incorporation and Tested as Inhibitors in APC/C assays. 
 
Cyclin B 1-95* ubiquitination is inhibited by Emi1 containing Tryptophan mutations in 
the C-terminal Tail.  Mutants that are not defective for inhibition (shown by green 
spheres) are suitable positions for BPA incorporation. 
 
  
 46 
in vivo Incorporation of BPA to Central Residues of Emi1 and Ube2s 
 
The most significant technical hurdle for UAA crosslinking is developing a 
protocol for incorporation of the chemical itself into the protein of interest.  The first of 
two strategies we employ is amber suppression technology, which has been developed for 
a number of years by multiple groups (Wang, Brock et al. 2001, Wang and Schultz 2001, 
Wu, Deiters et al. 2004, Xie, Wang et al. 2004, Young, Ahmad et al. 2010).  This in vivo 
incorporation methodology harnesses the native function of the host ribosomal translation 
machinery by supplying a new tRNA, an amino-acyl RNA synthetase, and a BPA amino 
acid precursor molecule.  BPA can be translated with the protein at specific sites by 
including an amber stop codon at the desired UAA site.  Relying on an evolved 
incorporation vector, amber codons do not exclusively recruit Release Factor 1 (RF1) to 
posit a translational “stop”, but also provide a T-stem loop structure that recruits both the 
BPA molecule and the synthetase.  At some ratio, BPA incorporation outcompetes 
stoppage and generates full-length protein to the next non-amber stop.  For our future 
studies, we utilize the most recently optimized, high-efficiency system available publicly; 
a vector called pEVOL-pBpF developed by Dr. Peter Schultz (Young, Ahmad et al. 
2010). 
 
Despite years of progress and development, the efficiency of BPA incorporation 
is highly unpredictable for this system, and invariably protein expression yields are 
significantly reduced, even for proteins without an amber-stop incorporation burden.  
This is due in part to the reliance of E. coli host proteins utilization of amber stop codons.  
Throughout the bacterial genome, hundreds of genes require the TAG codon for 
termination of translation, and through amber suppression technology these are 
efficiently replaced with BPA.  Presumably, this causes a decrease in the productivity of 
these cells during the cumbersome task of protein over-expression following chemical 
induction.  Nutrient-rich media partially overcomes these prohibitively low protein 
yields, in part through the allowance of high cell density at induction.  Following the 
published suggestions of the system’s developers, we systematically optimize many steps 
of the expression protocol to increase production of purified BPA-containing protein.  
For Emi1 and Ube2s we find only a few factors that improve upon the previously 
optimized system.  Auto-induction media (Studier 2005) produces approximately four-
fold more protein than LB with identical incorporation efficiency, when accompanied by 
co-induction with previously optimized concentrations of arabinose and IPTG at an 
optical density of 1.6 instead of 0.8, measured at 600nm.  Changing expression 
temperatures between 16°C and 30°C for 16 hours did not have a drastic effect, whereas 
37° induction for 4 hours was insufficient.  Concentration of BPA itself in the cultures 
was varied and found to be most effective at 0.2mM, in agreement with published 
findings (Young, Ahmad et al. 2010).  From our pGEX vector, this improved system is 
capable of yielding as much as 10mg per Liter, or amounts unsuitably low for 
purification.  
 
Interestingly, expression and incorporation efficiencies are changed drastically 
within a single construct, solely dependent upon the relative location of the TAG codon 
for BPA incorporation.  In Figure 4-2, Ube2s is expressed from a single construct using  
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Figure 4-2. Incorporation Efficiencies Are Evident from GST-Ube2s Pulldowns 
Following in vivo BPA Incorporation. 
 
BPA is introduced through amber suppression to several positions throughout Ube2s.  At 
some ratio, incorporation failures are visualized as quicker migrating bands of truncated 
molecular weight. 
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identical parameters but changing the amino-acid replaced with BPA for several mutants.  
BPA incorporation and overall expression are changed many-fold through a seemingly 
random mechanism that likely points to a poorly-understood mechanism of ribosomal 
incorporation reliant on either DNA or peptidyl sequences flanking the amber stop.  This 
effect is not an artifact of a single experiment, as completely new clones purified with a 
C-terminal LRRL deletion exhibit the same trend of expression and incorporation 
variation (Figure 4-3).  Through our optimized protocols and ability to perform 
expression at a large 24 liter scale for any low-level expression construct, we are able to 
produce BPA-containing proteins at essentially any position of Emi1 or Ube2s.  Using 
this methodology, BPA has been incorporated to over 50 constructs of Emi1 and Ube2s. 
 
 
Purification of BPA-containing Emi1 or Ube2s Following in vivo Incorporation 
 
 Incorporation of BPA site-specifically using amber suppression technology is 
only partially efficient, as described above, yielding both full-length protein with BPA 
and protein C-terminally truncated at the site of the amber stop-codon.  A number of 
purification strategies are used to separate full-length proteins from truncations, including 
C-terminal affinity tags and chromatographic separation based on size.  However, C-
terminal affinity tags are not optimal for Emi1 or Ube2s as both require a native C-
terminal LRRL sequence for APC/C-dependent activity.  Furthermore, though SEC is 
possible when the BPA replacement site is near the N-terminus, any C-terminal positions 
of BPA would create truncated proteins at nearly full-length, making separation by size 
impractical.  Luckily, for Emi1 and Ube2s, a highly basic C-terminal ~40 amino acid 
stretch allows for separation from the neutral, uncharged N-terminal region of these 
proteins more efficiently than SEC using cation exchange.  This does not, however, 
provide a means for purification of near full-length incorporation failures.  For this we 
develop an entirely new method for incorporation of BPA to C-terminal fragments of 
disordered proteins. 
 
 
Introduction of Fmoc BPA to C-terminal Residues of Emi1 and Ube2s 
 
To produce Emi1 or Ube2s with BPA near the C-terminus, we utilize a bacterial 
transpeptidase called sortase to covalently attach a preformed peptide with a purified 
protein.  This method has been used in the past for a variety of reasons (Bolscher, 
Oudhoff et al. 2011, Popp, Dougan et al. 2011, Guimaraes, Witte et al. 2013, Swee, 
Guimaraes et al. 2013, Theile, Witte et al. 2013, Strijbis and Ploegh 2014), and has been 
a popular method within our lab for applying N- or C-terminal fluorescent tags to 
proteins.  The sortase enzyme itself recognizes any exposed LPET^G sequence (^ 
denotes site of cleavage) within proteins or small polypeptides and catalyzes 
simultaneous cleavage and transpeptidation of substrates with N-terminal Glycine 
residues (Figure 4-4)(Popp, Antos et al. 2009).  
 
Before attempting BPA incorporation, we first identify a site within the C-
terminus of Emi1 capable of tolerating an LPET^G motif as a final product.  Assays  
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Figure 4-3. Ube2s BPA Using New Clones with C-terminal Deletion.  
 
SDS-PAGE of samples from GST-affinity pulldown reveals identical expression and 
incorporation ratios for new clones with C-terminal LRRL tail deletion. 
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Figure 4-4. Sortase-mediated Transpeptidation Attaches an Emi1 Tail Peptide to 
Emi1 Protein. 
 
Schematic Diagram and Sequence Information showing how Sortase fuses a C-terminal 
peptide of Emi1 sequence with purified Emi1 protein corresponding to N-terminal 
sequence.  This technique generates 3 mutations at the site of attachment, but yields 
otherwise wild-type full-length protein. 
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designed to test these final product mimics validate a region 23 residues from the C-
terminus of Emi1 as benign.  As proof of principle and in order to optimize sortase 
parameters for this system, peptides corresponding to these residues of Emi1 were 
synthesized, and Emi1 terminating in LPETGG is purified.  Following enzymatic 
reaction, full-length Emi1 can again be separated from truncated products through cation 
exchange and SEC.   
 
 
Establishing Positive Controls for Capturing Protein-Protein Interactions with BPA 
 
To validate this relatively complicated strategy for mapping protein-protein 
interactions in our multi-protein system, we first develop the technique using a robust 
two-protein complex.  In a previous study (Sato, Mimasu et al. 2011), Sato et.al were able 
to recapitulate a crystallizable (Nakamura, Nakano et al. 2007) interaction between 
mouse Gankyrin and a C-terminal domain of an AAA+ ATPase called S6 (S6C).  The 
authors replaced residues at the crystallized interface between Gankyrin and S6C with 
BPA in a variety of combinations.  Following extensive crosslinking and purification of 
the crosslinked product, the same crystals are formed and the structure is solved with a 
covalent BPA crosslink. The electron density map reveals the same molecular structure 
but with extra density corresponding to the crosslinked residues.  These constructs and 
protocols serve as a strong positive control for many aspects of BPA crosslinking 
including functionality of the synthesized UAA chemical itself, correct UV activation 
protocols and machinery, proper incorporation of BPA to proteins and our ability to 
monitor native protein-protein interactions through SDS-PAGE. 
 
 As seen in Figure 4-5, we are able to reproduce the protein-protein interactions 
described in literature, and we can validate that our crosslinker is correctly incorporated, 
specifically replacing residue Arg85 of gankyrin, which is capable of co-purifying with 
S6C as predicted from the study.  On a time-course of UV photoactivation, the covalently 
crosslinked product of Gankyrin-S6C is observed in denaturing SDS-PAGE experiments 
only in reactions containing the residues responsible for the interaction.  Interestingly, 
replacement of the receiving Glutamate 356 of S6C to Aspartate, a theoretically mild 
mutation, is incapable of BPA crosslinking.  These results are confirmatory that BPA 
incorporation and crosslinking behaves similarly to published results in a model system.   
 
 
Using Emi1 as a Positive Control for APC/C-specific Crosslinking and Detection 
 
With confidence that our BPA crosslinking methods report on direct protein-
protein interactions, and with the ability to generate and purify Emi1 and Ube2s proteins 
with BPA at any position, we aim to test site-specific crosslinking in the context of the 
APC/C.  Due to the vanishingly small quantities of recombinant APC/C we are able to 
generate, and to the transient nature of Ube2s-APC/C interactions, we first establish 
APC/C crosslinking with Emi1 as a positive control.  The tight-binding nature of Emi1, 
and our prior domain characterization and structure determination make this an attractive 
system for validation of this approach.   
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Figure 4-5. Gankyrin and S6C Are a Positive Control for BPA Crosslinking. 
 
This coommassie-stained SDS-PAGE gel of BPA crosslinking recapitulates published 
crosslinking for the Gankyrin-S6 complex.  Crosslinking is visualized as a higher 
molecular weight band appearing on a timecourse of UV photoactivation, and only in 
conditions where BPA within Gankyrin is expected to crosslink S6C.  
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We incorporate BPA to 8 positions among Emi1’s D-box, Linker domain, and C-
terminal tail as previously described.  1µM Emi1-BPA is mixed with 1µM APC/C-Cdh1 
and incubated for 30 minutes prior to photoactivation.  Photo-crosslinking is performed 
for 60-minutes using our optimized protocol, and reaction products are loaded to SDS-
PAGE gels.  Western blots with anti-His tag primary antibodies (Sigma) specific for a 
His-tagged Emi1 reveal high molecular-weight species indicative of APC/C crosslinking.  
Importantly, these crosslinks do not form when Emi1-BPA is mixed only with Cdh1 
absent of APC/C (Figure 4-6).  Interestingly, residues near the D-box of Emi1 form 
crosslinked products of two sizes, whereas crosslinked Tail residues migrate to a single 
position, indicative of binding to only one protein. 
 
 
Ube2s Interactions with APC/C at Multiple Locations Are Captured Through BPA 
Crosslinking 
 
In the context of the multi-subunit APC/C, specific crosslinks are visualized for 
Emi1-BPA.  This result validates this crosslinking approach as a means to capture and 
monitor binding events between specific residues of APC/C associating proteins.  We 
aim to highlight the usefulness of this tool not by recapitulating interactions that are well 
characterized, rather to report on previously unidentified contacts.  Although from our 
electron microscopy studies we have information to trace Emi1’s path along the APC/C 
architecture, very little is known about the location of Ube2s in the context of APC/C.  
We therefore employ photocrosslinking as an orthogonal approach to electron 
microscopy to glean information about the transient structure of Ube2s-bound APC/C.   
 
Residues surrounding E153 and I154 of Ube2s were chosen for crosslinking and 
are of general interest because they are kinetically implicated in an activation mechanism 
in experiments performed by Nick Brown at the onset of this part of the project.  A 
double mutant E153A–I154A version of Ube2s is not activated by the APC/C, and is 
therefore considered severely deficient in APC/C-dependent assays.  However, in APC/C 
independent reactions, where the inherent reactivity of Ube2s is tested in Ubiquitin 
transfer to an acceptor Ubiquitin, no defect is observed.  These results suggest that 
residues E153 and I154 contact the APC/C to direct Ubiquitination of APC/C-bound 
substrate Ubiquitins.  To visualize and characterize this interaction, I target residues 
along the pair of helices containing E153 and I154 for BPA incorporation.  Crosslinking 
is performed similarly to the optimized protocol established for Emi1, and products of the 
reaction are loaded to SDS-PAGE and monitored by western-blot analysis of a FLAG-tag 
on Ube2s. 
 
 
C-terminal Helices C and D of Ube2s Crosslink Specifically to APC2 and APC4 
 
BPA substitutions of several residues within this targeted region of Ube2s are 
crosslinked to APC/C-Cdh1 by co-mixing 1µM Ube2s with 1µM APC/C-Cdh1 for 30 
minutes prior to photoactivation.  Reactions are performed at sufficiently large volumes 
to allow the same reactions to be loaded many times to different gels, making it possible  
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Figure 4-6. His-Emi1 with BPA Reporting on D-box, Linker, and Tail 
Interactions with APC/C. 
 
This western blot of SDS-PAGE gel using anti-His antibodies specific for His-Emi1-
DLZT reveals APC/C dependent crosslinking.  Crosslinks observed for BPA positions 
surrounding the D-box are different from those observed for Emi1’s Tail. 
 
 
  
 55 
to western blot for several of the proteins involved in the interaction without introducing 
the variability associated with performing several experiments.   
 
 Crosslinking is performed with a number of controls to validate the specificity of 
the reaction:  UV exposure of Ube2s-BPA in the absence of APC/C reveals any non-
specific intramolecular crosslinking.  Furthermore, Ube2s-BPA proteins lacking the C-
terminal LRRL tail are tested to verify the crosslinking is dependent on specific 
recruitment of Ube2s to the APC/C, and does not report on non-specific, random 
interactions.  Negative crosslinking results in these control experiments strengthen our 
confidence in the effectiveness of our system to recapitulate native interactions between 
Ube2s and the APC/C. 
 
 Only upon activation with UV light, significant crosslinking is observed between 
residues E153, I154, and A158 of Ube2s and specific subunits of the APC/C (Figure 4-7, 
Figure 4-8, Figure 4-9).  Western blots specific for the FLAG-tag on Ube2s show 
migration patterns specific for two locations of Ube2s significantly larger than Ube2s 
protein itself.  These two alternate migrations of Ube2s persist throughout crosslinking of 
the three different BPA positions in this helix.  Further analysis of the same reactions 
reveals that only certain subunits of the APC/C are modified with Ube2s.  Antibodies 
specific for APC4 protein and APC2 protein reveal that both of these subunits are 
modified with Ube2s in specific reactions.  Furthermore, a second antibody for the Strep-
tag on APC4 confirms there is not a problem with antibody specificity; rather the APC4 
subunit is specifically crosslinked by Ube2s in these reactions.  These results begin to 
explain the mechanism of Ube2s activation by the APC/C.  The C-terminal helices of 
Ube2s that include residues E153, I154, and A158 make contact with the APC2/APC4 
region of the platform, and this is likely responsible for either direct activation of the E2, 
or as a means for E2 positioning near its substrate, or both.  Since the methodologies for 
residue-specific identification of the crosslinked protein side-chains are not fully 
developed, future studies will be required to elucidate what specific APC2 and APC4 
contacts are being made, and how they facilitate Ube2s activity. 
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Figure 4-7. Crosslinking Between Residue E153 of Ube2s and APC/C-Cdh1. 
 
Western blots of Ube2s-APC/C photocrosslinking reactions are performed with the 
indicated antibodies.  Ube2s migration in SDS-PAGE gels is specifically slowed to two 
positions.  These positions correlate with slower migration visualized for APC2 and 
APC4, suggesting specific crosslinking to these subunits.  These results validate an RL-
tail recruitment dependency for these APC/C-Ube2s interactions, and an APC/C 
dependency for Ube2s crosslinking.  
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Figure 4-8. Crosslinking Between Residue I154 of Ube2s and APC/C-Cdh1. 
 
Western blots of Ube2s-APC/C photocrosslinking reactions are performed with the 
indicated antibodies.  Ube2s migration in SDS-PAGE gels is specifically slowed to two 
positions.  These positions correlate with slower migration visualized for APC2 and 
APC4, suggesting specific crosslinking to these subunits.  These results validate an RL-
tail recruitment dependency for these APC/C-Ube2s interactions, and an APC/C 
dependency for Ube2s crosslinking.  
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Figure 4-9. Crosslinking Between Residue A158 of Ube2s and APC/C-Cdh1. 
 
Western blots of Ube2s-APC/C photocrosslinking reactions are performed with the 
indicated antibodies.  Ube2s migration in SDS-PAGE gels is specifically slowed to two 
positions.  These positions correlate with slower migration visualized for APC2 and 
APC4, suggesting specific crosslinking to these subunits.  These results validate an RL-
tail recruitment dependency for these APC/C-Ube2s interactions, and an APC/C 
dependency for Ube2s crosslinking.  
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CHAPTER 5.    DISCUSSION 
 
 
APC/C-Cdh1-Emi1 Structure at High Resolution 
 
 Two years after completion of the work described in this dissertation, a unique 
opportunity to analyze the high-resolution structure of APC/C with Emi1 bound was 
made possible both by data generated by our lab and our collaborators, as well as by a 
journal article published by the Barford lab in Cambridge, UK (Chang, Zhang et al. 
2015).  Both high-resolution structures combined with the structural groundwork 
provided by our lab (Frye, Brown et al. 2013) yield similar information about the 
orientation of Emi1 on APC/C and the interactions between them, and accordingly both 
are studied to provide insights into the results obtained prior to their discovery. 
 
 
Emi1 D-box Engages the Cdh1 and APC10 Co-receptors 
 
The most obvious region of the structure to validate is the D-box binding site 
between the β-propeller surface of Cdh1 and the jelly-roll fold of APC10, as this is a 
well-established substrate recruitment mechanism of the APC/C (Passmore, McCormack 
et al. 2003, Carroll, Enquist-Newman et al. 2005, Buschhorn, Petzold et al. 2011).  By 
examining both the density map (EMD: 2924) and the model associated with it (PDB ID 
4UI9)(Chang, Zhang et al. 2015), it is evident that Emi1 is recruited to these co-receptors 
as expected (Figure 5-1).  Though the published model contains a modified D-box motif 
within Emi1, (T323I), it is reasonable to expect that the native Emi1 D-box sequence, 
although relatively weak, is capable of acting as a pseudo-substrate motif and inhibits 
substrate recruitment in this way. 
 
 
Emi1 ZBR Alanine Scan Informs on Residues in the Interface 
 
We next analyze the electron density ascribed to the Emi1 ZBR.  This region of 
the electron density map is very convincingly correct for both placement and orientation 
of the ZBR structure that was solved in our lab.  The structured ZBR fits quite well 
within map density, even at low contour and provides insight to the direction of travel 
from the N-terminus to C-terminus, which is useful when considering the Linker domain 
between the D-box motif and ZBR domain.  When comparing the modeled structure with 
our Alanine scanning mutagenesis results (Figure 5-2), no major discrepancies are 
observed.  In fact, the surface that was suggested as an APC/C interacting motif points 
directly to the RING subunit of APC11.  When taking the biochemistry and structures 
together, the function of these residues is likely a mix between inter-molecular contacts 
with APC11 and intramolecular contacts supporting and stabilizing the structure of the 
ZBR itself as well as the disordered regions following the structured Linker helix.  
Furthermore, the APC11 RING is implicated as the catalytic module for the APC/C, and 
direct binding to this mobile element restrains its mobility and directly inhibits the CRL 
catalytic mechanism of APC/C.   
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Figure 5-1. Emi1 D-box Is Co-recruited to Cdh1 and APC10. 
 
Analysis of APC/C-Cdh1-Emi1 structural model PDB: 4UI9 from the Barford lab.  Cdh1 
is colored purple, Emi1 is red, and APC10 is orange, all other components of the model 
are green.  Emi1 is co-recruited to Cdh1 and APC10 in the same way substrates have 
been shown to bind.   
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Figure 5-2. Emi1 ZBR Associates with APC11 and Utilizes the Surface 
Discovered in the ZBR Alanine Scan, and the Functional Linker Forms a Helix 
Between APC11 and APC1 
 
Emi1, red, is represented as a cartoon with “very deficient” mutants colored in yellow. 
These mutations map to a surface that helps to organize the helical, essential Linker 
domain, and may bind directly to APC/C. 
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Functional Linker Domain Between the D-box and ZBR Is Visualized and Localizes 
to APC1 and APC11 
 
In the electron density maps, there is evidence for a structured region of Emi1 that 
protrudes from the N-terminus of the folded ZBR domain.  The Linker domain of Emi1 is 
perfectly suited to fill this density, as it is directly N-terminal of the ZBR and has been 
shown through mutational analysis to be essential for function.  Though it is difficult to 
be certain of the register of the helix shown in the maps due to lack of side-chain density 
at the achieved resolution, the published model for Emi1 in this region places residues 
Y356 and R358 in positions for contact with APC1 and APC11.  Since mutation of these 
residues, and not deletion of 10 residues directly N-terminal of them, causes a defect in 
Emi1’s APC/C inhibition, the model likely confirms our mutational analysis of this 
region.   
 
 
Emi1 Tail Binds APC/C at the Base of the Platform and Inhibits Ube2s Tail 
 
Finally, a small helical portion of Emi1’s Tail is visualized binding to the base of 
the APC/C platform region, and makes contacts specifically with APC2 and APC4.  
Importantly, the published manuscript also visualizes the C-terminal tail of Ube2s 
binding to this same region in a moderate-resolution structure of a Ubch10-Ube2s fusion 
protein.  Though the model suggested by the authors does not place the perfectly 
conserved and critical LRRL tail of these proteins in the density, it does account for 
Em1i’s ability to specifically inhibit the activity of Ube2s in our assays.  Furthermore, the 
overall orientation of the entirety of Emi1 is exactly as we report it to be, with the D-box 
bound to the coactivator Cdh1 at the top of the catalytic cavity, the ZBR interfering with 
catalytic machinery in the peripheral center of the cavity, and the Emi1 C-terminal tail 
associating near the base of the platform (Figure 5-3). 
 
 
Retrospective Analysis of BPA Incorporation Methodologies 
  
 A combination of two methodologies for incorporation of BPA to target proteins 
was presented in this dissertation.  Amber suppression technology has been developed for 
more than 10 years and the newest systems are easy to use and are capable of generating 
milligrams of pure BPA-containing protein per liter of culture.  Though this technique 
has limitations and drawbacks, I would suggest that amber suppression for in vivo 
incorporation of a wide variety of unnatural amino acids is the more robust system for a 
number of reasons.  By scaling up the volume of bacterial culture, it is quite easy to 
overcome the problem of inefficient incorporation and reduced expression.  Furthermore, 
these problems can likely be overcome by shifting the position of the amber stop codon 
to residues surrounding the residue of interest as this seems to have a random but strong 
effect on both protein expression and UAA incorporation.  Typically genes of interest are 
expressed with C-terminal affinity tags, allowing for immediate separation of 
prematurely truncated proteins, and this makes amber suppression a powerful and simple 
technique for scanning through several positions of a protein to isolate conditions that 
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Figure 5-3. Emi1 Traverses the APC/C Architecture as Visualized by Negative 
Stain EM Experiments. 
 
Left, Negative stain reconstructions of APC/C-Emi1 with Doa1 propeller insertions, 
compared with Emi1-DLZT lacking insertions, Middle, allowed us to visualize the 
overall topology of APC/C-Cdh1-Emi1. This is consistent with Emi1 spanning the 
catalytic core as in PDB ID 4UI9, Right.  
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enable site-specific crosslinking and inform on the biology of protein-protein 
interactions.   
 
 Both Emi1 and Ube2s have essential C-terminal tail residues that must be 
preserved and therefore these proteins cannot tolerate affinity tags at the C-terminus.  As 
explained previously, this makes in vivo incorporation of BPA to residues near the C-
terminus impossible as the incorporation defects are unable to be isolated from full-length 
proteins.  To circumvent this issue, we established a method that allows for BPA 
incorporation to a C-terminal peptide, which is subsequently ligated to the protein 
through sortase-mediated transpeptidation.  The unmodified protein is then smaller than 
the modified protein by an entire ~20-40 residue peptide, even in cases where the UAA is 
at positions near the extreme C-terminus, and this allows for purification by size, or in 
our case by ion exchange chromatography mediated by the highly basic C-terminal tail. 
 
 The second method, although essential for overcoming our specific problem, has 
a number of drawbacks that make it an impractical method for large-scale use.  Firstly, 
the final yield of protein is limited by the initial yield of peptide.  By pre-incorporating 
BPA via Fmoc chemistry, the final quantity of peptide represents the upper limit for 
peptide-incorporated protein.  In fact, for C-terminal labeling, the best sortase reaction 
efficiency is achieved by having the peptide in vast excess over protein, and this makes 
the yields of full-length protein quite limiting, on the order of 50µg to 500µg, depending 
on the scale of the enzymatic reaction and the success of the purification strategy.   
Purification from the enzyme following the reaction is also critical, as any contaminating 
sortase enzyme can readily cleave the product and remove the BPA-peptide.  For this, we 
purify our 1mL reaction mixtures over gradient NaCl IEX, followed by SEC, a strategy 
which further decreases the overall yield.  A variety of other methodologies, including 
self-splicing C-terminal inteins (Batjargal, Walters et al. 2015) and cell strains that lack 
the ability to truncate (Lajoie, Rovner et al. 2013) have been developed recently, and are 
likely a more practical and useful method for overcoming this problem.   
 
 
Multisite Binding as a General Mechanism of Inhibition 
 
 
Multivalency Is Common in Biology 
 
 We discover here a multisite, avid mechanism of APC/C inhibition by Emi1. 
Emi1's exhibition of multivalent inhibition is not unique; rather it is representative of an 
entire class of inhibitors, both natural and designed.  Even beyond inhibition, 
multivalency mediates many biological and synthetic interactions, and investigation into 
the properties of other multivalent interactions of both the protein and drug-design 
frameworks helps to better place Emi1's functionalities and critical role among a well-
established mechanism of biological function.   
 
 Multivalent interactions can be loosely defined as cooperative interactions of 
multiple connected binding groups during a single binding process.  An oversimplified 
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example is Velcro, in which many very weak hook-fiber interactions are connected on a 
single surface and work together to create a stronger interaction. This definition 
necessitates both a multisite receptor (APC/C in our case) and a multisite ligand (Emi1 in 
our case), as a large number of ligands with only one site of interaction for the receptor 
do not exhibit cooperativity as a connected binding group.  Early studies of these types of 
phenomenon derived from characterization of interactions in inorganic chemistry 
including chelation and other metallic properties, and only later were similar cooperative 
binding effects discovered occurring in organic molecules and subsequently throughout 
biology.  It is now known that multivalent interactions occur throughout the protein 
interactome, with extensive characterization of lectin interactions with carbohydrates and 
sugars (Lepenies, Lee et al. 2013, Wittmann and Pieters 2013, Visini, Jin et al. 2015), and 
toxin interactions with cell-surface receptors (Wolfhagen, Torensma et al. 1994, 
Nishikawa 2003).  Other, more simple 2-site interactions such as a single p27 protein 
binding both to Skp2 and Cks1 (Hao, Zheng et al. 2005), Cand1 inhibition of Cul1-Roc1 
(Goldenberg, Cascio et al. 2004), Cbl proteins as  multivalent adapters for tyrosine kinase 
functions (Tsygankov, Teckchandani et al. 2001, Swaminathan and Tsygankov 2006) 
exhibit the same principle of multi-site interactions, and recently, useful tools such as 
structural databases (Meyer and Knapp 2014) have been developed to aid in the 
molecular understanding of these natural interactions. 
 
 One such biological interaction is observed and found to be essential at the 
telomeres of DNA by multivalent association of the proteins Rif1 and Rif2 with Rap1.  
These proteins bind to the telomeric DNA repeats and form a sterically occlusive cap 
called a telosome that inhibits telomerase cleavage and transcriptional silencing.  A 
recent study aims to characterize how single or multivalent interactions between Rif1 and 
Rap1 as well as Rif2 and Rap1 lead to higher-order associations with DNA, considering 
only Rap1 is believed to bind DNA (Leuthauser, Thomas et al. 1992, Shi, Bunker et al. 
2013).  Two Rif1 sites are capable of binding two different, distant Rap1 sites or 
molecules, which can simultaneously be bound by another Rif1 or Rif2 molecule.  In this 
case, multivalency seems to be less important for avidity affects leading to high affinity 
interactions, and more important for establishing a network of linked interactions which, 
through multiple binding sites for both Rif1 and Rif2 at distinct locations within Rap1, 
enables the dissociation of each of these single protein-protein interactions to be 
overcome by having multiple association events.  From this perspective, Emi1 
multivalency can also be characterized as a series of connected binding events.  Not only 
do the multiple binding sites of Emi1 each contribute to the combined kinetics of 
association with APC/C, but they also lessen the overall dissociation constant, increasing 
the stability of the APC/C-Emi1 complex.  For instance, temporary dissociation of the 
relatively weak D-box is overcome by association kinetics of the Linker, ZBR, and Tail 
regions of Emi1, such that Emi1 does not wholly dissociate, but self-stabilizes on the 
APC/C.  This may account for the ability to maintain stoichiometric complex throughout 
the relatively long purification of APC/C-Emi1 complexes for EM, including an 
overnight gradient centrifugation step in vitro, and throughout interphase of the cell-cycle 
in vivo. 
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 Perhaps more importantly, though, are the applications of this natural 
phenomenon to the rational design of synthetic inhibitors and multivalent drug-like 
molecules for treatment of a wide range of human pathologies.  Indeed, both targeted 
development of specific systems, such as trimeric PCNA binding peptides (Bozza, Yang 
et al. 2012), selectivity of inhibitory compounds of the BCL-2 family (Bruncko, Wang et 
al. 2015), and hundreds of other structure guided drug design efforts, as well as broadly 
developed biotechnologies like multivalent architectural scaffolds and nanostructures (Li, 
Choi et al. 2014) have enabled significant improvements in therapeutic discoveries in 
recent years.  Rational drug design efforts typically utilize known structural information 
of both the target and the inhibitor to intelligently enhance drug potency or specificity.  
This enables biochemists to build larger or more kinetically productive inhibitors, or to 
specifically target only certain proteins or complexes within structurally or functionally 
similar families.   
 
Analogous to rational drug design, sequence-directed population studies of 
libraries of modified inhibitory peptides are also a powerful technique for improving 
known inhibitors.  For example, a group of Italian researchers modify a known CamKII 
inhibitory peptide and established a library of similar but non-identical peptides to probe 
the functional consequences of their mutations (Gomez-Monterrey, Sala et al. 2013).  The 
authors identify a 17-mer peptide with improved specificity for CamKII that is capable of 
penetrating cells and inhibiting the RAS/RAF/MEK/ERK cellular signaling pathway. To 
a certain extent, our work mimics this mutational analysis approach for peptide 
enhancement, such as our generation of a Super-D-box chimera, and it is possible that 
even milder mutations of this APC/C recruitment motif would be superior to Emi1’s 
native D-box, like the T323I mutation observed in the Barford structure.  In consideration 
of developing peptides or chemicals that mimic Emi1 form or function, studies like these 
provide an exciting glance at the possible outcomes of these works.  Similarly, the 
structural and biochemical information we have discovered about Emi1 presented here 
could be developed further into more potent or selective APC/C inhibitory compounds.  
Through visualization of the surfaces of APC/C that are important for catalysis, and by 
studying the interactions that dictate Emi1 association with several functionally diverse 
regions of the complex, it is easy to imagine development of small molecules or peptides 
which would mimic these functions. 
 
 
Targeting APC/C with Pharmacological Inhibitors  
 
 A variety of activating mutations have been shown to dysregulate the APC/C and 
lead to cancers (Penas, Ramachandran et al. 2011), and blocking mitotic exit is an 
effective approach for stimulating tumor cell death.  For these reasons, the APC/C has 
very recently become an attractive target for development of pharmacological inhibitors.  
Only recently has sufficient biochemical and structural data been generated to enable 
APC/C targeted drug development, and as such, only 2 non-biological inhibitors have 
been established for the APC/C to date; APCin (APC inhibitor) and TAME (tosyl-
arginine-methyl-ester) (Zeng and King 2012, Sackton, Dimova et al. 2014, Lub, Maes et 
al. 2015).  APCin shares structural similarity to the RxxL D-box motif of substrates, and 
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a Cdc20-APCin cocrystal structure reveals that the inhibitor binds competitively to the 
coactivator’s D-box binding site.  This substrate-recruitment inhibitor causes stabilization 
of APC/C substrates in mitotic Xenopus laevis extracts, making for a promising target in 
APC/C regulation.  TAME mimics an essential C-terminal IR tail of Cdc20, Cdh1, and 
APC10.  Each of these proteins is coordinated by an IR-tail binding groove within APC3 
(Yamaguchi, Yu et al. 2015).  Both APCin and TAME inhibit the APC/C at distinct sites, 
and their combination treatment yields a synergistic effect in Xenopus extracts (Sackton, 
Dimova et al. 2014).  
 
 These pharmacological inhibitors have been developed to mimic and therefore 
block the biological activation of APC/C and have established therapeutic potential by 
stimulating cell death of multiple myeloma cells.  Our biochemical and structural 
characterization of the biological inhibitor, Emi1, reveals novel functionalities within 
APC/C that are ideal drug targets.  Much like the C-terminal IR-tail interaction of the 
coactivator proteins with APC3, our conserved C-terminal RL tail of Emi1 is absolutely 
essential both for its function as an inhibitor, and for Ube2s’s function as an E2.  
Evolutionary pressure has already developed a regulated inhibitor of Ube2s recruitment, 
and this site is likely an ideal target for small molecule mimic of an RL tail.  Our studies 
with Emi1 also reveal an unfortunate truth: much remains unknown about the true 
mechanisms of action of this critically important cell cycle regulator.  In our process of 
isolating the function of a very small inhibitory subdomain, we discovered 4 functional 
elements blocking 3 critical functionalities on a single face of our 1,200 kDa complex.  It 
is quite possible that further regulation of this complex is yet to be discovered, and that a 
number of critical protein-protein interaction sites have not been visualized and will be 
viable targets for future drug discovery as well.  Indeed, all of the Emi1 data generated 
here has highlighted the necessity of future studies of this complex and it’s workings, and 
provides a framework for piecing together the complex networks of interactions that 
regulate and activate the APC/C’s function. 
 
 
MCC Inhibition of APC/C 
 
 Utilizing what we have learned about APC/C activity from our studies with Emi1 
and from recent high-resolution information, we can further analyze the mechanism of 
the other inhibitors, including the other major biological APC/C inhibitor, the Mitotic 
Checkpoint Complex.  Although limited by the low resolution of current human APC/C-
MCC structures, it seems likely that the MCC blocks the substrate recruitment 
mechanism of APC/C based on structures observed in crystals and EM (Herzog, 
Primorac et al. 2009, Chao, Kulkarni et al. 2012).  What is unclear is whether the MCC is 
capable of inhibiting one or both of the APC/C specific E2s, Ubch10 and Ube2s.  By 
directly contacting and covering much of the catalytic core, it is plausible that Ubch10 is 
precluded from its canonical APC/C binding sites (Brown, VanderLinden et al. 2015), 
but it is also conceivable that Emi1 potently inhibits Ube2s recruitment where MCC 
inhibits only Ubch10 recruitment.  This could provide a means for regulation of E2-
specific ubiquitination activities, as it is known that the extent and topology of 
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ubiquitination regulates the fate of the target, from degradative targeting to signaling and 
other outcomes.  
 
 
Cand1 Is Both a Competitor and Activator of CRLs. 
 
 Canonical CRL complexes are engaged by another protein, CAND1, which, like 
Emi1, was long considered to be a general inhibitor.  CAND1 associates with Cullins 
blocking their activation by Nedd8ylation, and obstructing Skp1 association with F-box 
proteins.  Despite structural evidence supporting competitive inhibition of SCF, and in 
vitro assays characterizing the effect, many in vivo experiments suggest CAND1-
dependent activation of SCF activity in cells.  This paradox persisted for several years 
until recent experiments discover a cryptic mechanism that supports both in vitro 
inhibition and in vivo activation of SCF by CAND1.  In this case, the answer comes from 
binding kinetics:  CAND1 drastically increases the dissociation of F-box proteins from 
Cullin, but has no effect on F-box association constants.  By effectively removing a 
stably bound accessory protein, CAND1 serves as an exchange factor to enable Cullin 
protein assembly with the hundreds of known adaptor complexes.   
 
Analysis of the multisite, multifunctional binding of CAND1 allows speculation 
about a general model of SCF assembly and activation in a broader, cellular context: 
Perhaps, since CAND1 is unable to bind to Nedd8-modified Cullin proteins, a novel 
mechanism is employed by SCF to degrade large pools of a subset of substrates, and then 
Cullin returns to promiscuous association with F-box proteins to sample a variety of new 
targets.  In this model, a CRL encounters a substrate, nedd8ylation activates the CRL, and 
CAND1 association is not possible.  The absence of the CAND1 exchange factor allows 
specific, processive destruction of substrates recruited only by the currently associated F-
box protein.  In time, deneddylases remove Nedd8, and CAND1 association allows 
Cullin to collaborate with new F-box proteins, targeting new substrate pools.  This model 
couples CRL activity with substrate availability, F-box protein expression and 
localization, and the competitive interplay between neddylation and CAND1 association, 
providing ample means of regulatory control by cellular cues. 
 
 
Could Emi1’s Multisite Binding Provide More Than an Inhibitory Role? 
 
 Due to the cryptic, multisite CAND1 activation mechanism, this exchange factor 
was mistaken as a competitive inhibitor of CRLs.  Emi1 also employs a similar multisite 
association with the many functional domains within APC/C, which begs the question: is 
Emi1 doing more than APC/C association and inhibition?  Kinetic studies of Emi1 as 
performed by a postdoc in the lab, Nick Brown, in conjunction with this work suggest 
that the multisite binding of Emi1 creates an overall affinity so tight that it cannot be 
measured in our assays, likely in the picomolar range.  This distinguishes Emi1’s 
constants for dissociation and association from those of Cand1, suggesting that it is not 
an exchange factor by the same mechanism.  It is also possible that by associating with a 
variety of distant parts of the APC/C, that Emi1 could provide a means of stabilization of 
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the multi-protein APC/C.  Indeed, Emi1 lowers the inherently flexibility of the APC/C in 
our EM studies and therefore allows for higher resolution structural information to be 
obtained. 
 
 
What Is the Rest of Emi1 for? 
 
 Our characterization of Emi1 function paired with recent structural information 
only accounts for the C-terminal 1/3 of Emi1’s sequence.  Though a few residues within 
the N-terminal sequence of Emi1 have been shown to be responsible for Emi1’s own 
regulation, it is not clear that this is the only function of this part of the protein.  
Interestingly, Emi1 contains an F-box that is benign for APC/C inhibition, but may serve 
other roles in the cell.  F-box proteins are well-established functional partners the CRL 
family of ligases, and Emi1’s F-box binds with high affinity to Skp1, another major 
Cullin-associating protein.  As of yet a functional relationship between Emi1’s F-box and 
CRL activity have not been established, but beyond Emi1’s original discovery based on 
Skp1 association, the F-box has not been studied extensively.  There may be cell-type 
specific, or stress response related functions of this domain that are yet to be understood. 
 
Furthermore, residues besides the well-characterized phosphodegrons have been 
shown to be post-translationally modified with phosphorylation by the action of Cyclin-
dependent-kinases (Moshe, Bar-On et al. 2011).  This modification of Emi1’s C-terminus 
renders it insufficient at inhibiting the APC/C, providing a Plk1-mediated degradation 
independent manner of Emi1 regulation.  A further six phosphorylation sites in the N-
terminus of Emi1 have been discovered, but no kinase or functional outcome of 
phosphorylation has been tested.  It is plausible that environment-specific modification of 
Emi1 by a variety of factors represents a tunable control of Emi1 regulation, and 
therefore regulation of APC/C E3 ligase activity and regulation of cellular signaling 
pathways in which APC/C substrates are involved.  
 
  
 70 
 
LIST OF REFERENCES 
 
 
Ban, K. H., J. Z. Torres, J. J. Miller, A. Mikhailov, M. V. Nachury, J. J. Tung, C. L. 
Rieder and P. K. Jackson (2007). "The END network couples spindle pole assembly to 
inhibition of the anaphase-promoting complex/cyclosome in early mitosis." Dev Cell 
13(1): 29-42. 
Batjargal, S., C. R. Walters and E. J. Petersson (2015). "Inteins as traceless purification 
tags for unnatural amino acid proteins." J Am Chem Soc 137(5): 1734-1737. 
Berndsen, C. E. and C. Wolberger (2014). "New insights into ubiquitin E3 ligase 
mechanism." Nat Struct Mol Biol 21(4): 301-307. 
Bochis, O. V., B. Fetica, C. Vlad, P. Achimas-Cadariu and A. Irimie (2015). "The 
Importance of Ubiquitin E3 Ligases, SCF and APC/C, in Human Cancers." Clujul Med 
88(1): 9-14. 
Bolscher, J. G., M. J. Oudhoff, K. Nazmi, J. M. Antos, C. P. Guimaraes, E. Spooner, E. 
F. Haney, J. J. Garcia Vallejo, H. J. Vogel, W. van't Hof, H. L. Ploegh and E. C. 
Veerman (2011). "Sortase A as a tool for high-yield histatin cyclization." FASEB J 25(8): 
2650-2658. 
Bozza, W. P., K. Yang, J. Wang and Z. Zhuang (2012). "Developing peptide-based 
multivalent antagonists of proliferating cell nuclear antigen and a fluorescence-based 
PCNA binding assay." Anal Biochem 427(1): 69-78. 
Bremm, A. and D. Komander (2011). "Emerging roles for Lys11-linked polyubiquitin in 
cellular regulation." Trends Biochem Sci 36(7): 355-363. 
Brown, N. G., R. VanderLinden, E. R. Watson, R. Qiao, C. R. Grace, M. Yamaguchi, F. 
Weissmann, J. J. Frye, P. Dube, S. Ei Cho, M. L. Actis, P. Rodrigues, N. Fujii, J. M. 
Peters, H. Stark and B. A. Schulman (2015). "RING E3 mechanism for ubiquitin ligation 
to a disordered substrate visualized for human anaphase-promoting complex." Proc Natl 
Acad Sci U S A 112(17): 5272-5279. 
Brown, N. G., E. R. Watson, F. Weissmann, M. A. Jarvis, R. VanderLinden, C. R. Grace, 
J. J. Frye, R. Qiao, P. Dube, G. Petzold, S. E. Cho, O. Alsharif, J. Bao, I. F. Davidson, J. 
J. Zheng, A. Nourse, I. Kurinov, J. M. Peters, H. Stark and B. A. Schulman (2014). 
"Mechanism of polyubiquitination by human anaphase-promoting complex: RING 
repurposing for ubiquitin chain assembly." Mol Cell 56(2): 246-260. 
Bruncko, M., L. Wang, G. S. Sheppard, D. C. Phillips, S. K. Tahir, J. Xue, S. Erickson, S. 
Fidanze, E. Fry, L. Hasvold, G. J. Jenkins, S. Jin, R. A. Judge, P. J. Kovar, D. Madar, P. 
Nimmer, C. Park, A. M. Petros, S. H. Rosenberg, M. L. Smith, X. Song, C. Sun, Z. F. 
Tao, X. Wang, Y. Xiao, H. Zhang, C. Tse, J. D. Leverson, S. W. Elmore and A. J. Souers 
 71 
(2015). "Structure-guided design of a series of MCL-1 inhibitors with high affinity and 
selectivity." J Med Chem 58(5): 2180-2194. 
Buschhorn, B. A., G. Petzold, M. Galova, P. Dube, C. Kraft, F. Herzog, H. Stark and J. 
M. Peters (2011). "Substrate binding on the APC/C occurs between the coactivator Cdh1 
and the processivity factor Doc1." Nat Struct Mol Biol 18(1): 6-13. 
Carroll, C. W., M. Enquist-Newman and D. O. Morgan (2005). "The APC subunit Doc1 
promotes recognition of the substrate destruction box." Curr Biol 15(1): 11-18. 
Cenciarelli, C., D. S. Chiaur, D. Guardavaccaro, W. Parks, M. Vidal and M. Pagano 
(1999). "Identification of a family of human F-box proteins." Curr Biol 9(20): 1177-
1179. 
Chang, L., Z. Zhang, J. Yang, S. H. McLaughlin and D. Barford (2015). "Atomic 
structure of the APC/C and its mechanism of protein ubiquitination." Nature 522(7557): 
450-454. 
Chao, W. C., K. Kulkarni, Z. Zhang, E. H. Kong and D. Barford (2012). "Structure of the 
mitotic checkpoint complex." Nature 484(7393): 208-213. 
Chatterjee, A., J. Guo, H. S. Lee and P. G. Schultz (2013). "A genetically encoded 
fluorescent probe in mammalian cells." J Am Chem Soc 135(34): 12540-12543. 
Chin, J. W., T. A. Cropp, J. C. Anderson, M. Mukherji, Z. Zhang and P. G. Schultz 
(2003). "An expanded eukaryotic genetic code." Science 301(5635): 964-967. 
Chin, J. W., T. A. Cropp, S. Chu, E. Meggers and P. G. Schultz (2003). "Progress toward 
an expanded eukaryotic genetic code." Chem Biol 10(6): 511-519. 
Chin, J. W., A. B. Martin, D. S. King, L. Wang and P. G. Schultz (2002). "Addition of a 
photocrosslinking amino acid to the genetic code of Escherichiacoli." Proc Natl Acad Sci 
U S A 99(17): 11020-11024. 
Chin, J. W., S. W. Santoro, A. B. Martin, D. S. King, L. Wang and P. G. Schultz (2002). 
"Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli." J Am 
Chem Soc 124(31): 9026-9027. 
da Fonseca, P. C., E. H. Kong, Z. Zhang, A. Schreiber, M. A. Williams, E. P. Morris and 
D. Barford (2011). "Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 
as the D-box co-receptor." Nature 470(7333): 274-278. 
Deiters, A., T. A. Cropp, M. Mukherji, J. W. Chin, J. C. Anderson and P. G. Schultz 
(2003). "Adding amino acids with novel reactivity to the genetic code of Saccharomyces 
cerevisiae." J Am Chem Soc 125(39): 11782-11783. 
Deshaies, R. J. and C. A. Joazeiro (2009). "RING domain E3 ubiquitin ligases." Annu 
Rev Biochem 78: 399-434. 
 72 
Dikic, I., S. Wakatsuki and K. J. Walters (2009). "Ubiquitin-binding domains - from 
structures to functions." Nature reviews. Molecular cell biology 10(10): 659-671. 
Dimova, N. V., N. A. Hathaway, B. H. Lee, D. S. Kirkpatrick, M. L. Berkowitz, S. P. 
Gygi, D. Finley and R. W. King (2012). "APC/C-mediated multiple monoubiquitylation 
provides an alternative degradation signal for cyclin B1." Nat Cell Biol 14(2): 168-176. 
Dong, X., K. H. Zavitz, B. J. Thomas, M. Lin, S. Campbell and S. L. Zipursky (1997). 
"Control of G1 in the developing Drosophila eye: rca1 regulates Cyclin A." Genes Dev 
11(1): 94-105. 
Dou, H., L. Buetow, G. J. Sibbet, K. Cameron and D. T. Huang (2012). "BIRC7-E2 
ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING 
dimer." Nat Struct Mol Biol 19(9): 876-883. 
Duda, D. M., L. A. Borg, D. C. Scott, H. W. Hunt, M. Hammel and B. A. Schulman 
(2008). "Structural insights into NEDD8 activation of cullin-RING ligases: 
conformational control of conjugation." Cell 134(6): 995-1006. 
Eletr, Z. M., D. T. Huang, D. M. Duda, B. A. Schulman and B. Kuhlman (2005). "E2 
conjugating enzymes must disengage from their E1 enzymes before E3-dependent 
ubiquitin and ubiquitin-like transfer." Nat Struct Mol Biol 12(10): 933-934. 
Evans, T., E. T. Rosenthal, J. Youngblom, D. Distel and T. Hunt (1983). "Cyclin: a 
protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage 
division." Cell 33(2): 389-396. 
Freemont, P. S., I. M. Hanson and J. Trowsdale (1991). "A novel cysteine-rich sequence 
motif." Cell 64(3): 483-484. 
Frye, J. J., N. G. Brown, G. Petzold, E. R. Watson, C. R. Grace, A. Nourse, M. A. Jarvis, 
R. W. Kriwacki, J. M. Peters, H. Stark and B. A. Schulman (2013). "Electron microscopy 
structure of human APC/C(CDH1)-EMI1 reveals multimodal mechanism of E3 ligase 
shutdown." Nat Struct Mol Biol 20(7): 827-835. 
Furman, J. L., M. Kang, S. Choi, Y. Cao, E. D. Wold, S. B. Sun, V. V. Smider, P. G. 
Schultz and C. H. Kim (2014). "A genetically encoded aza-Michael acceptor for covalent 
cross-linking of protein-receptor complexes." J Am Chem Soc 136(23): 8411-8417. 
Garnett, M. J., J. Mansfeld, C. Godwin, T. Matsusaka, J. Wu, P. Russell, J. Pines and A. 
R. Venkitaraman (2009). "UBE2S elongates ubiquitin chains on APC/C substrates to 
promote mitotic exit." Nat Cell Biol 11(11): 1363-1369. 
Goldenberg, S. J., T. C. Cascio, S. D. Shumway, K. C. Garbutt, J. Liu, Y. Xiong and N. 
Zheng (2004). "Structure of the Cand1-Cul1-Roc1 complex reveals regulatory 
mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases." 
Cell 119(4): 517-528. 
 73 
Gomez-Monterrey, I., M. Sala, M. R. Rusciano, S. Monaco, A. S. Maione, G. Iaccarino, 
P. Tortorella, A. M. D'Ursi, M. Scrima, A. Carotenuto, G. De Rosa, A. Bertamino, E. 
Vernieri, P. Grieco, E. Novellino, M. Illario and P. Campiglia (2013). "Characterization 
of a selective CaMKII peptide inhibitor." Eur J Med Chem 62: 425-434. 
Guimaraes, C. P., M. D. Witte, C. S. Theile, G. Bozkurt, L. Kundrat, A. E. Blom and H. 
L. Ploegh (2013). "Site-specific C-terminal and internal loop labeling of proteins using 
sortase-mediated reactions." Nat Protoc 8(9): 1787-1799. 
Hansen, D. V., A. V. Loktev, K. H. Ban and P. K. Jackson (2004). "Plk1 regulates 
activation of the anaphase promoting complex by phosphorylating and triggering 
SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1." Mol Biol Cell 15(12): 
5623-5634. 
Hao, B., N. Zheng, B. A. Schulman, G. Wu, J. J. Miller, M. Pagano and N. P. Pavletich 
(2005). "Structural basis of the Cks1-dependent recognition of p27(Kip1) by the 
SCF(Skp2) ubiquitin ligase." Mol Cell 20(1): 9-19. 
He, J., W. C. Chao, Z. Zhang, J. Yang, N. Cronin and D. Barford (2013). "Insights into 
degron recognition by APC/C coactivators from the structure of an Acm1-Cdh1 
complex." Mol Cell 50(5): 649-660. 
Hershko, A. and H. Heller (1985). "Occurrence of a polyubiquitin structure in ubiquitin-
protein conjugates." Biochem Biophys Res Commun 128(3): 1079-1086. 
Herzog, F., I. Primorac, P. Dube, P. Lenart, B. Sander, K. Mechtler, H. Stark and J. M. 
Peters (2009). "Structure of the anaphase-promoting complex/cyclosome interacting with 
a mitotic checkpoint complex." Science 323(5920): 1477-1481. 
Hsu, J. Y., J. D. Reimann, C. S. Sorensen, J. Lukas and P. K. Jackson (2002). "E2F-
dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1)." 
Nat Cell Biol 4(5): 358-366. 
Huang, D. T., D. W. Miller, R. Mathew, R. Cassell, J. M. Holton, M. F. Roussel and B. 
A. Schulman (2004). "A unique E1-E2 interaction required for optimal conjugation of the 
ubiquitin-like protein NEDD8." Nat Struct Mol Biol 11(10): 927-935. 
Huang, D. T., A. Paydar, M. Zhuang, M. B. Waddell, J. M. Holton and B. A. Schulman 
(2005). "Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's 
E1." Mol Cell 17(3): 341-350. 
Ikeda, F. and I. Dikic (2008). "Atypical ubiquitin chains: new molecular signals. 'Protein 
Modifications: Beyond the Usual Suspects' review series." EMBO Rep 9(6): 536-542. 
Jarvis, M. A., N. G. Brown, E. R. Watson, R. VanderLinden, B. A. Schulman and J. M. 
Peters (2016). "Measuring APC/C-Dependent Ubiquitylation In Vitro." Methods Mol 
Biol 1342: 287-303. 
 74 
Javahishvili, T., A. Manibusan, S. Srinagesh, D. Lee, S. Ensari, M. Shimazu and P. G. 
Schultz (2014). "Role of tRNA orthogonality in an expanded genetic code." ACS Chem 
Biol 9(4): 874-879. 
King, R. W., J. M. Peters, S. Tugendreich, M. Rolfe, P. Hieter and M. W. Kirschner 
(1995). "A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific 
conjugation of ubiquitin to cyclin B." Cell 81(2): 279-288. 
Komander, D. and M. Rape (2012). "The ubiquitin code." Annu Rev Biochem 81: 203-
229. 
Lajoie, M. J., A. J. Rovner, D. B. Goodman, H. R. Aerni, A. D. Haimovich, G. 
Kuznetsov, J. A. Mercer, H. H. Wang, P. A. Carr, J. A. Mosberg, N. Rohland, P. G. 
Schultz, J. M. Jacobson, J. Rinehart, G. M. Church and F. J. Isaacs (2013). "Genomically 
recoded organisms expand biological functions." Science 342(6156): 357-360. 
Latres, E., D. S. Chiaur and M. Pagano (1999). "The human F box protein beta-Trcp 
associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin." 
Oncogene 18(4): 849-854. 
Lee, H. S., R. D. Dimla and P. G. Schultz (2009). "Protein-DNA photo-crosslinking with 
a genetically encoded benzophenone-containing amino acid." Bioorg Med Chem Lett 
19(17): 5222-5224. 
Lepenies, B., J. Lee and S. Sonkaria (2013). "Targeting C-type lectin receptors with 
multivalent carbohydrate ligands." Adv Drug Deliv Rev 65(9): 1271-1281. 
Leuthauser, S. W., J. E. Thomas and D. L. Guernsey (1992). "Oncogenes in X-ray-
transformed C3H 10T1/2 mouse cells and in X-ray-induced mouse fibrosarcoma (RIF-1) 
cells." Int J Radiat Biol 62(1): 45-51. 
Li, M. H., S. K. Choi, P. R. Leroueil and J. R. Baker, Jr. (2014). "Evaluating binding 
avidities of populations of heterogeneous multivalent ligand-functionalized 
nanoparticles." ACS Nano 8(6): 5600-5609. 
Lin, Y., W. C. Hwang and R. Basavappa (2002). "Structural and functional analysis of 
the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10." J Biol Chem 
277(24): 21913-21921. 
Liu, C. C., A. V. Mack, M. L. Tsao, J. H. Mills, H. S. Lee, H. Choe, M. Farzan, P. G. 
Schultz and V. V. Smider (2008). "Protein evolution with an expanded genetic code." 
Proc Natl Acad Sci U S A 105(46): 17688-17693. 
Lu, D., J. R. Girard, W. Li, A. Mizrak and D. O. Morgan (2015). "Quantitative 
framework for ordered degradation of APC/C substrates." BMC Biol 13(1): 96. 
 75 
Lu, D., J. Y. Hsiao, N. E. Davey, V. A. Van Voorhis, S. A. Foster, C. Tang and D. O. 
Morgan (2014). "Multiple mechanisms determine the order of APC/C substrate 
degradation in mitosis." J Cell Biol 207(1): 23-39. 
Lub, S., A. Maes, K. Maes, K. De Veirman, E. De Bruyne, E. Menu, K. Fostier, A. 
Kassambara, J. Moreaux, D. Hose, X. Leleu, R. W. King, K. Vanderkerken and E. Van 
Valckenborgh (2015). "Inhibiting the anaphase promoting complex/cyclosome induces a 
metaphase arrest and cell death in multiple myeloma cells." Oncotarget. 
Margottin-Goguet, F., J. Y. Hsu, A. Loktev, H. M. Hsieh, J. D. Reimann and P. K. 
Jackson (2003). "Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin 
ligase activates the anaphase promoting complex to allow progression beyond 
prometaphase." Dev Cell 4(6): 813-826. 
Meyer, T. and E. W. Knapp (2014). "Database of protein complexes with multivalent 
binding ability: Bival-Bind." Proteins 82(5): 744-751. 
Miller, J. J., M. K. Summers, D. V. Hansen, M. V. Nachury, N. L. Lehman, A. Loktev 
and P. K. Jackson (2006). "Emi1 stably binds and inhibits the anaphase-promoting 
complex/cyclosome as a pseudosubstrate inhibitor." Genes Dev 20(17): 2410-2420. 
Min, M., T. E. Mevissen, M. De Luca, D. Komander and C. Lindon (2015). "Efficient 
APC/C substrate degradation in cells undergoing mitotic exit depends on K11 ubiquitin 
linkages." Mol Biol Cell 26(24): 4325-4332. 
Morgan, D. O. (2007). The Cell Cycle:  Principles of Control. 
Moshe, Y., O. Bar-On, D. Ganoth and A. Hershko (2011). "Regulation of the action of 
early mitotic inhibitor 1 on the anaphase-promoting complex/cyclosome by cyclin-
dependent kinases." J Biol Chem 286(19): 16647-16657. 
Nagai, M. and T. Ushimaru (2014). "Cdh1 is an antagonist of the spindle assembly 
checkpoint." Cell Signal 26(10): 2217-2222. 
Nakamura, Y., K. Nakano, T. Umehara, M. Kimura, Y. Hayashizaki, A. Tanaka, M. 
Horikoshi, B. Padmanabhan and S. Yokoyama (2007). "Structure of the oncoprotein 
gankyrin in complex with S6 ATPase of the 26S proteasome." Structure 15(2): 179-189. 
Nishikawa, K. (2003). "[Shiga toxin neutralizers with multivalent carbohydrates]." 
Seikagaku 75(7): 604-609. 
Ohe, M., D. Inoue, Y. Kanemori and N. Sagata (2007). "Erp1/Emi2 is essential for the 
meiosis I to meiosis II transition in Xenopus oocytes." Dev Biol 303(1): 157-164. 
Ohe, M., Y. Kawamura, H. Ueno, D. Inoue, Y. Kanemori, C. Senoo, M. Isoda, N. Nakajo 
and N. Sagata (2010). "Emi2 inhibition of the anaphase-promoting complex/cyclosome 
absolutely requires Emi2 binding via the C-terminal RL tail." Mol Biol Cell 21(6): 905-
913. 
 76 
Olsen, S. K. and C. D. Lima (2013). "Structure of a ubiquitin E1-E2 complex: insights to 
E1-E2 thioester transfer." Mol Cell 49(5): 884-896. 
Ostapenko, D., J. L. Burton and M. J. Solomon (2012). "Identification of anaphase 
promoting complex substrates in S. cerevisiae." PLoS One 7(9): e45895. 
Pashkova, N., L. Gakhar, S. C. Winistorfer, L. Yu, S. Ramaswamy and R. C. Piper 
(2010). "WD40 repeat propellers define a ubiquitin-binding domain that regulates 
turnover of F box proteins." Mol Cell 40(3): 433-443. 
Passmore, L. A., E. A. McCormack, S. W. Au, A. Paul, K. R. Willison, J. W. Harper and 
D. Barford (2003). "Doc1 mediates the activity of the anaphase-promoting complex by 
contributing to substrate recognition." EMBO J 22(4): 786-796. 
Penas, C., V. Ramachandran and N. G. Ayad (2011). "The APC/C Ubiquitin Ligase: 
From Cell Biology to Tumorigenesis." Front Oncol 1: 60. 
Pendergrast, P. S., Y. Chen, Y. W. Ebright and R. H. Ebright (1992). "Determination of 
the orientation of a DNA binding motif in a protein-DNA complex by 
photocrosslinking." Proc Natl Acad Sci U S A 89(21): 10287-10291. 
Peters, J. M. (2006). "The anaphase promoting complex/cyclosome: a machine designed 
to destroy." Nat Rev Mol Cell Biol 7(9): 644-656. 
Philipps, B., M. Forstner and L. M. Mayr (2005). "A baculovirus expression vector 
system for simultaneous protein expression in insect and mammalian cells." Biotechnol 
Prog 21(3): 708-711. 
Pickart, C. M. and M. J. Eddins (2004). "Ubiquitin: structures, functions, mechanisms." 
Biochim Biophys Acta 1695(1-3): 55-72. 
Plechanovova, A., E. G. Jaffray, M. H. Tatham, J. H. Naismith and R. T. Hay (2012). 
"Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis." Nature 
489(7414): 115-120. 
Popp, M. W., J. M. Antos and H. L. Ploegh (2009). "Site-specific protein labeling via 
sortase-mediated transpeptidation." Curr Protoc Protein Sci Chapter 15: Unit 15 13. 
Popp, M. W., S. K. Dougan, T. Y. Chuang, E. Spooner and H. L. Ploegh (2011). 
"Sortase-catalyzed transformations that improve the properties of cytokines." Proc Natl 
Acad Sci U S A 108(8): 3169-3174. 
Pruneda, J. N., P. J. Littlefield, S. E. Soss, K. A. Nordquist, W. J. Chazin, P. S. Brzovic 
and R. E. Klevit (2012). "Structure of an E3:E2 approximately Ub Complex Reveals an 
Allosteric Mechanism Shared among RING/U-box Ligases." Mol Cell 47(6): 933-942. 
 77 
Reimann, J. D., E. Freed, J. Y. Hsu, E. R. Kramer, J. M. Peters and P. K. Jackson (2001). 
"Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase 
promoting complex." Cell 105(5): 645-655. 
Reimann, J. D., B. E. Gardner, F. Margottin-Goguet and P. K. Jackson (2001). "Emi1 
regulates the anaphase-promoting complex by a different mechanism than Mad2 
proteins." Genes Dev 15(24): 3278-3285. 
Sackton, K. L., N. Dimova, X. Zeng, W. Tian, M. Zhang, T. B. Sackton, J. Meaders, K. 
L. Pfaff, F. Sigoillot, H. Yu, X. Luo and R. W. King (2014). "Synergistic blockade of 
mitotic exit by two chemical inhibitors of the APC/C." Nature 514(7524): 646-649. 
Sarikas, A., T. Hartmann and Z. Q. Pan (2011). "The cullin protein family." Genome Biol 
12(4): 220. 
Sato, S., S. Mimasu, A. Sato, N. Hino, K. Sakamoto, T. Umehara and S. Yokoyama 
(2011). "Crystallographic study of a site-specifically cross-linked protein complex with a 
genetically incorporated photoreactive amino acid." Biochemistry 50(2): 250-257. 
Schreiber, A., F. Stengel, Z. Zhang, R. I. Enchev, E. H. Kong, E. P. Morris, C. V. 
Robinson, P. C. da Fonseca and D. Barford (2011). "Structural basis for the subunit 
assembly of the anaphase-promoting complex." Nature 470(7333): 227-232. 
Scott, D. C., V. O. Sviderskiy, J. K. Monda, J. R. Lydeard, S. E. Cho, J. W. Harper and 
B. A. Schulman (2014). "Structure of a RING E3 Trapped in Action Reveals Ligation 
Mechanism for the Ubiquitin-like Protein NEDD8." Cell 157(7): 1671-1684. 
Shi, T., R. D. Bunker, S. Mattarocci, C. Ribeyre, M. Faty, H. Gut, A. Scrima, U. Rass, S. 
M. Rubin, D. Shore and N. H. Thoma (2013). "Rif1 and Rif2 shape telomere function and 
architecture through multivalent Rap1 interactions." Cell 153(6): 1340-1353. 
Strijbis, K. and H. L. Ploegh (2014). "Secretion of circular proteins using sortase." 
Methods Mol Biol 1174: 73-83. 
Studier, F. W. (2005). "Protein production by auto-induction in high density shaking 
cultures." Protein Expr Purif 41(1): 207-234. 
Sudakin, V., D. Ganoth, A. Dahan, H. Heller, J. Hershko, F. C. Luca, J. V. Ruderman and 
A. Hershko (1995). "The cyclosome, a large complex containing cyclin-selective 
ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis." Mol Biol 
Cell 6(2): 185-197. 
Summers, M. K., B. Pan, K. Mukhyala and P. K. Jackson (2008). "The unique N 
terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and 
enhances checkpoint regulation of the APC." Mol Cell 31(4): 544-556. 
Swaminathan, G. and A. Y. Tsygankov (2006). "The Cbl family proteins: ring leaders in 
regulation of cell signaling." J Cell Physiol 209(1): 21-43. 
 78 
Swee, L. K., C. P. Guimaraes, S. Sehrawat, E. Spooner, M. I. Barrasa and H. L. Ploegh 
(2013). "Sortase-mediated modification of alphaDEC205 affords optimization of antigen 
presentation and immunization against a set of viral epitopes." Proc Natl Acad Sci U S A 
110(4): 1428-1433. 
Tang, W., J. Q. Wu, C. Chen, C. S. Yang, J. Y. Guo, C. D. Freel and S. Kornbluth 
(2010). "Emi2-mediated inhibition of E2-substrate ubiquitin transfer by the anaphase-
promoting complex/cyclosome through a D-box-independent mechanism." Mol Biol Cell 
21(15): 2589-2597. 
Tenno, T., K. Fujiwara, H. Tochio, K. Iwai, E. H. Morita, H. Hayashi, S. Murata, H. 
Hiroaki, M. Sato, K. Tanaka and M. Shirakawa (2004). "Structural basis for distinct roles 
of Lys63- and Lys48-linked polyubiquitin chains." Genes Cells 9(10): 865-875. 
Theile, C. S., M. D. Witte, A. E. Blom, L. Kundrat, H. L. Ploegh and C. P. Guimaraes 
(2013). "Site-specific N-terminal labeling of proteins using sortase-mediated reactions." 
Nat Protoc 8(9): 1800-1807. 
Tian, W., B. Li, R. Warrington, D. R. Tomchick, H. Yu and X. Luo (2012). "Structural 
analysis of human Cdc20 supports multisite degron recognition by APC/C." Proc Natl 
Acad Sci U S A 109(45): 18419-18424. 
Tischer, T., E. Hormanseder and T. U. Mayer (2012). "The APC/C inhibitor XErp1/Emi2 
is essential for Xenopus early embryonic divisions." Science 338(6106): 520-524. 
Tsygankov, A. Y., A. M. Teckchandani, E. A. Feshchenko and G. Swaminathan (2001). 
"Beyond the RING: CBL proteins as multivalent adapters." Oncogene 20(44): 6382-
6402. 
Varadan, R., O. Walker, C. Pickart and D. Fushman (2002). "Structural properties of 
polyubiquitin chains in solution." J Mol Biol 324(4): 637-647. 
Verschuren, E. W., K. H. Ban, M. A. Masek, N. L. Lehman and P. K. Jackson (2007). 
"Loss of Emi1-dependent anaphase-promoting complex/cyclosome inhibition deregulates 
E2F target expression and elicits DNA damage-induced senescence." Mol Cell Biol 
27(22): 7955-7965. 
Visini, R., X. Jin, M. Bergmann, G. Michaud, F. Pertici, O. Fu, A. Pukin, T. R. Branson, 
D. M. Thies-Weesie, J. Kemmink, E. Gillon, A. Imberty, A. Stocker, T. Darbre, R. J. 
Pieters and J. L. Reymond (2015). "Structural Insight into Multivalent Galactoside 
Binding to Pseudomonas aeruginosa Lectin LecA." ACS Chem Biol 10(11): 2455-2462. 
Visintin, R., S. Prinz and A. Amon (1997). "CDC20 and CDH1: a family of substrate-
specific activators of APC-dependent proteolysis." Science 278(5337): 460-463. 
Wang, L., A. Brock, B. Herberich and P. G. Schultz (2001). "Expanding the genetic code 
of Escherichia coli." Science 292(5516): 498-500. 
 79 
Wang, L. and P. G. Schultz (2001). "A general approach for the generation of orthogonal 
tRNAs." Chem Biol 8(9): 883-890. 
Wang, W. and M. W. Kirschner (2013). "Emi1 preferentially inhibits ubiquitin chain 
elongation by the anaphase-promoting complex." Nat Cell Biol 15(7): 797-806. 
Willems, A. R., M. Schwab and M. Tyers (2004). "A hitchhiker's guide to the cullin 
ubiquitin ligases: SCF and its kin." Biochim Biophys Acta 1695(1-3): 133-170. 
Wittmann, V. and R. J. Pieters (2013). "Bridging lectin binding sites by multivalent 
carbohydrates." Chem Soc Rev 42(10): 4492-4503. 
Wolfhagen, M. J., R. Torensma, A. C. Fluit, C. J. Aarsman, M. Jansze and J. Verhoef 
(1994). "Multivalent binding of toxin A from Clostridium difficile to carbohydrate 
receptors." Toxicon 32(1): 129-132. 
Wu, N., A. Deiters, T. A. Cropp, D. King and P. G. Schultz (2004). "A genetically 
encoded photocaged amino acid." J Am Chem Soc 126(44): 14306-14307. 
Wu, P. Y., M. Hanlon, M. Eddins, C. Tsui, R. S. Rogers, J. P. Jensen, M. J. Matunis, A. 
M. Weisman, C. Wolberger and C. M. Pickart (2003). "A conserved catalytic residue in 
the ubiquitin-conjugating enzyme family." Embo J 22(19): 5241-5250. 
Wu, T., Y. Merbl, Y. Huo, J. L. Gallop, A. Tzur and M. W. Kirschner (2010). "UBE2S 
drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex." 
Proc Natl Acad Sci U S A 107(4): 1355-1360. 
Xie, J., L. Wang, N. Wu, A. Brock, G. Spraggon and P. G. Schultz (2004). "The site-
specific incorporation of p-iodo-L-phenylalanine into proteins for structure 
determination." Nat Biotechnol 22(10): 1297-1301. 
Yamaguchi, M., S. Yu, R. Qiao, F. Weissmann, D. J. Miller, R. VanderLinden, N. G. 
Brown, J. J. Frye, J. M. Peters and B. A. Schulman (2015). "Structure of an APC3-
APC16 complex: insights into assembly of the anaphase-promoting complex/cyclosome." 
J Mol Biol 427(8): 1748-1764. 
Ye, Y. and M. Rape (2009). "Building ubiquitin chains: E2 enzymes at work." Nat Rev 
Mol Cell Biol 10(11): 755-764. 
Yeh, F. L., L. Tung and T. H. Chang (2016). "Detection of Protein-Protein Interaction 
Within an RNA-Protein Complex Via Unnatural-Amino-Acid-Mediated Photochemical 
Crosslinking." Methods Mol Biol 1421: 175-189. 
Young, T. S., I. Ahmad, J. A. Yin and P. G. Schultz (2010). "An enhanced system for 
unnatural amino acid mutagenesis in E. coli." J Mol Biol 395(2): 361-374. 
 80 
Yu, H., R. W. King, J. M. Peters and M. W. Kirschner (1996). "Identification of a novel 
ubiquitin-conjugating enzyme involved in mitotic cyclin degradation." Curr Biol 6(4): 
455-466. 
Zeng, X. and R. W. King (2012). "An APC/C inhibitor stabilizes cyclin B1 by 
prematurely terminating ubiquitination." Nat Chem Biol 8(4): 383-392. 
Zhang, Z., L. Chang, J. Yang, N. Conin, K. Kulkarni and D. Barford (2013). "The four 
canonical tpr subunits of human APC/C form related homo-dimeric structures and stack 
in parallel to form a TPR suprahelix." J Mol Biol 425(22): 4236-4248. 
 
 
 
  
 81 
VITA 
 
 
 Edmond Watson was born in San Diego, California in 1987.  He graduated from 
Lambuth University in Jackson, TN with a Bachelor of Science degree in 2009.  
Following a 15-month research internship with the USDA at University of Tennessee’s 
WTREC in Jackson, TN, he moved to Memphis, TN and joined the Integrated Program 
in Biomedical Sciences at the University of Tennessee Health Science Center in 2010.  
He carried out his dissertation research in the lab of Dr. Brenda Schulman at St. Jude 
Children’s Research Hospital and is expected to receive his Ph.D. in May 2016.   
 
 
Publications 
 
 
*Brown, N.G., *R. VanderLinden, *E. R. Watson, et.al, in review. 
 
Brown, N. G., R. VanderLinden, E. R. Watson, R. Qiao, C. R. Grace, M. Yamaguchi, F. 
Weissmann, J. J. Frye, P. Dube, S. Ei Cho, M. L. Actis, P. Rodrigues, N. Fujii, J. M. 
Peters, H. Stark and B. A. Schulman (2015). "RING E3 mechanism for ubiquitin ligation 
to a disordered substrate visualized for human anaphase-promoting complex." Proc Natl 
Acad Sci U S A 112(17): 5272-5279. 
 
Brown, N. G., E. R. Watson, F. Weissmann, M. A. Jarvis, R. VanderLinden, C. R. 
Grace, J. J. Frye, R. Qiao, P. Dube, G. Petzold, S. E. Cho, O. Alsharif, J. Bao, I. F. 
Davidson, J. J. Zheng, A. Nourse, I. Kurinov, J. M. Peters, H. Stark and B. A. Schulman 
(2014). "Mechanism of polyubiquitination by human anaphase-promoting complex: 
RING repurposing for ubiquitin chain assembly." Mol Cell 56(2): 246-260. 
 
Frye, J. J., N. G. Brown, G. Petzold, E. R. Watson, C. R. Grace, A. Nourse, M. A. Jarvis, 
R. W. Kriwacki, J. M. Peters, H. Stark and B. A. Schulman (2013). "Electron microscopy 
structure of human APC/C(CDH1)-EMI1 reveals multimodal mechanism of E3 ligase 
shutdown." Nat Struct Mol Biol 20(7): 827-835. 
 
Jarvis, M. A., N. G. Brown, E. R. Watson, R. VanderLinden, B. A. Schulman and J. M. 
Peters (2016). "Measuring APC/C-Dependent Ubiquitylation In Vitro." Methods Mol 
Biol 1342: 287-303. 
 
Li, G., W. Ci, S. Karmakar, K. Chen, R. Dhar, Z. Fan, Z. Guo, J. Zhang, Y. Ke, L. Wang,  
M. Zhuang, S. Hu, X. Li, L. Zhou, X. Li, M. F. Calabrese, E. R. Watson, S. M. Prasad, 
C. Rinker-Schaeffer, S. E. Eggener, T. Stricker, Y. Tian, B. A. Schulman, J. Liu and K. 
P. White (2014). "SPOP promotes tumorigenesis by acting as a key regulatory hub in 
kidney cancer." Cancer Cell 25(4): 455-468. 
 
Lu, H., L. Li, E. R. Watson, R. W. Williams, E. E. Geisert, M. M. Jablonski and L. Lu 
(2011). "Complex interactions of Tyrp1 in the eye." Mol Vis 17: 2455-2468. 
 82 
 
Pierce, W. K., C. R. Grace, J. Lee, A. Nourse, M. R. Marzahn, E. R. Watson, A. A. 
High, J. Peng, B. A. Schulman and T. Mittag (2015). "Multiple Weak Linear Motifs 
Enhance Recruitment and Processivity in SPOP-Mediated Substrate Ubiquitination." J 
Mol Biol. 
 
 
* denotes equal author contribution 
